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Abstract 
 
The astrocytes, oligodendrocytes and microglia make up a significant 
proportion of the cells of the CNS.  In recent years, there has been a burgeoning 
interest in the role of glial cells, in neurodegenerative disease.  These cell types have 
been shown to play diverse roles in neuroinflammation, bioenergetics, signalling and 
intracellular oxidative balance, amongst others. Studies on Parkinson's, Alzheimer's, 
Huntington's and prion diseases suggest that the misfolded intra- or extra-cellular 
proteins that characterize these diseases could interfere with glial cell functions. I 
have developed and characterized an in vitro astrocyte primary cell culture.  I have 
used this to look at the changes in glial glutamate transporter levels in the presence of 
mutant htt and to conduct a set of calcium experiments. These experiments provide 
essential tools for future studies into glial biology in neurodegeneration.  
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1. Introduction 
1.1. Glia 
Central nervous system (CNS) glia (Oligodendrocytes, Microglia and 
Astrocytes) represent an understudied heterogeneous group of cells. Historically, glia 
have been thought of as inert support cells, but more recent science suggests a much 
wider role.  Oligodendrocytes serve to preserve saltatory conduction via nodes of 
ranvier, regulate axon diameter during development, maintain axon health and inhibit 
axonal growth and regeneration (Baumann and Pham-Dinh 2001).  Microglia are the 
resident CNS phagocytic and immunocompetent cells.  They secrete cytokines that 
promote, modulate and/or reduce brain inflammatory responses depending on the 
brain environment. Microglia also secrete important neuroprotective molecules (eg. 
BDNF, NGF, NT-3) as well as various cytotoxic substances, such as reactive oxygen 
species (ROS), complement proteins and proteinases, during neurological diseases 
and brain injury (Kim and de Vellis 2005).  Astrocytes have a role in the regulation of 
extracellular ion concentration and pH, maintenance of the blood brain barrier, 
metabolism, the coupling of neuronal activity to cerebral blood flow, immune 
support, glucose transport, glutamate homeostasis, neuronal differentiation, axon 
guidance, synapse formation, modulation of synaptic function and transmission, 
neurotrophic support and protection of neurons from oxidative stress (Maragakis and 
Rothstein 2006; Seth and Koul 2008). 
 
1.2. Astrocytes and Misfolded Protein 
Given the diverse roles of glia in normal brain function, it stands to reason that 
the dysfunction of these cells might contribute to neurological diseases. Astrocytes, in 
particular, are of interest as so many of their functions are involved, directly or 
indirectly, in promoting neuronal health and survival.  Astrocyte dysfunction has been 
observed in many diseases, including the ‘protein misfolding disorders’ 
(proteinopathies). These include the most common and devastating of neurological 
disorders:  Parkinson’s Disease (PD), Amyotrophic Lateral Sclerosis (ALS), 
Alzheimer’s Disease (AD), prion diseases and Huntington’s Disease (HD) which is a 
polyglutamine (polyQ) disorder (Ross and Poirier 2004; Meredith 2005).  These 
disorders are characterized by a failure of cellular protein folding and/or degradation  
machinery that compromises cell viability and function, which progresses to cell 
death and disease. These diseases all exhibit an accumulation of abnormal protein 
deposits known as ‘amyloids’.  Depending on the disease, different proteins aggregate 
inside or outside cells (e.g. α-synuclein, SOD1, PrP
C, Aβ, tau and huntingtin).  It is a 
matter of debate in current literature (Ross and Poirier 2004) whether the process of 
forming aggregates is neuroprotective or neurotoxic, however, it is widely accepted 
that protein aggregation and misfolding can interfere with cellular function and kill 
cells.  Intra- or extra-cellular protein aggregates exist within or around astrocytes in 
all these diseases.   
Potentially, every astrocyte function could be adversely affected by the 
presence of misfolded proteins.  However, there are a few known astrocytic 
dysfunctions that seem to occur in all the above diseases, which may have 
consequences in terms of neuronal health. These include glutamate toxicity, energetic 
deficits, vascular problems, inflammation and oxidative stress. 
 
1.3. Excitotoxicity 
  Glutamate is the most abundant excitatory neurotransmitter in the CNS.  
Glutamate acts at the synapse primarily through the ligand-gated ion channels 
(iGluR’s) named after their specific synthetic agonists α-3-hydroxy-5-methyl-4-
isoxazole propionic acid (AMPA), kainate, and N-methyl-D-aspartate (NMDA) 1, 
(reviewed in (Madden 2002).  There also exists a family of metabotropic glutamate 
receptors (mGluR’s) which are G-protein coupled (D'Antoni, Berretta et al. 2008).  
Both types of receptors are found on both the pre- and postsynaptic terminals as well 
as the astrocytes surrounding the synapse.  It is a well-established idea that excess 
extracellular glutamate kills neurons.  Current science suggests that there are two 
mechanisms involved in this phenomenon, known as excitotoxicity.  The activation of 
iGluR’s causes intracellular ion concentrations to alter, particularly Na
+ and Ca
2+.  
Even in the absence of extracellular Ca
2, glutamate-exposed hippocampi (Rothman 
1985) and retinal neurons (Olney, Price et al. 1986) swell in an acute toxic 
irreversible fashion mediated by Na
+.  However, it seems likely that Ca
2+ influx is 
more important than Na
+ incursion. In cultures with minimal Na
+, but physiological 
concentrations of extracelluar Ca
2+, neurons degenerate over time after exposure to  
glutamate and this is halted via removal of the Ca
2+ from the medium (Choi, 
Maulucci-Gedde et al. 1987).  Excess cytosolic Ca
2+ can cause mitochondrial 
uncoupling and the over-activation of potentially damaging enzymes such as 
proteases, nitric oxygen synthase, protein kinases, endonucleases and calcineurins.  
This can lead to mitochondrial disruption, oxidative stress, cytoskeletal reorganization 
and apoptosis (Arundine and Tymianski 2004; Nicholls 2008).                            
Glutamate excitoxicity seems to be a fundamental mechanism of neurodegeneration 
across all of the most common protein misfolding disorders. In patients with, or in 
models of, AD, ALS, PD and HD, there are glutamate transport defects and a 
downregulation of the astrocytic excitatory amino acid transporter 2 (EAAT2) or 
glutamate transporter-1 (GLT-1), which, in all cases, is likely to contribute to ongoing 
neuronal death.  EAAT2 accounts for roughly 95% of glutamate uptake in the human 
brain (Danbolt 2001).  In AD, ALS and HD, EAAT2 loss has been measured in the 
post mortem human brain (Rothstein, Van Kammen et al. 1995; Li, Mallory et al. 
1997; Hassel, Tessler et al. 2008) and in animal models (Masliah, Alford et al. 2000; 
Bendotti, Tortarolo et al. 2001; Lievens, Woodman et al. 2001; Howland, Liu et al. 
2002).  In PD, EAAT2 loss has only been measured in animal models (Dervan, 
Meshul et al. 2004; Chung, Chen et al. 2008).  The mechanisms of astrocyte EAAT2 
loss seem to be disease-specific. In AD and ALS, EAAT2 loss seems to occur at the 
protein translational level, as EAAT2 mRNA levels are not decreased (Rothstein, Van 
Kammen et al. 1995; Li, Mallory et al. 1997), whereas in HD, EAAT2 loss seems to 
happen at both the mRNA and protein levels (Lievens, Woodman et al. 2001; Hassel, 
Tessler et al. 2008). In all the above cases, EAAT2 loss seems to precede widespread 
neuronal death in the affected regions. In the PD models, the mechanism of EAAT2 
loss is yet to be determined.  Excitotoxicity, in transmissible spongiform 
encephalopathies, is thought to occur (Scallet and Ye 1997) but it does not appear to 
be a well-studied phenomena. There is however, one recent paper that suggests the 
endogenous cellular prion protein (PrP
c) is involved in regulating NMDA receptor 
activity and that its absence can lead to enhanced glutamate toxicity (Khosravani, 
Zhang et al. 2008). 
 
  Shin, Fang et al. (2005) showed that intranuclear htt aggregates form in R6/2  
glial cells and that these mice have a reduced expression of GLT-1 and a decreased 
glutamate uptake.  They also demonstrated that HD-knock in mice and patients have 
intranulear htt aggregates.  In the concluding experiments of this paper, they looked at 
the infection of cultured astrocytes with adenoviruses expressing either exon-1 of the 
htt gene with 23Q or 130Q linked to Green Florescent Protein (GFP).  These virus-
infected cells had a reduced expression of GLT-1 and a decreased glutamate uptake.  
Coculture of these adenovirus-infected astrocytes with wild-type neurons caused the 
neurons to cease expressing Microtubule Associated Protein 2 (MAP2).  A glutamate 
receptor blocker rescued these changes indicating that mutant polyglutamine 
expanded htt in astrocytes can promote neuronal excitotoxicity.  The next paper from 
this lab very much emphasises the importance of glial cell dysfunction in HD.  
Bradford, Shin et al. 2009 expressed an N-terminal fragment of htt with either 25 or 
160 glutamines under a glial fibrillary acidic protein (GFAP) promotor.  The Q160 
mice showed increased gliosis, decreased GLT-1 expression, decreased glutamate 
uptake, reduced lifespan and impaired behavioural performance on the Rotorod test.  
This paper is the first to describe a mechanism for transporter loss in HD. They 
demonstrated that mutant huntingtin binds to the GLT-1 transcription factor Sp1 and 
negatively effects the Sp1-dependent transcription of GLT-1 by reducing Sp1 
occupancy of the GLT-1 promotor.  The most recent paper from this lab (Bradford, 
Shin et al.) showed that distinct neurological phenotypes from expressing mutant htt 
under a GFAP promotor are not present when the glutamine repeat is 98Q in length.  
However, they then crossed these mice with N171-82Q mice.  N171-82Q mice 
express the first 171 amino acids of huntingtin and a Q82 polyglutamine repeat under 
a neuronal promotor.  N171-82Q mice do not express mutant htt in astrocytes.  The 
offspring that express both N171-82Q and astrocyte 98Q-GFP have a worse motor 
behavioural phenotype from 18 weeks of age onwards than N171-82Q alone and the 
double transgenics have a shorter lifespans, providing evidence for the import of glial 
mutant htt in HD.  These mice could potentially provide models to test every other 
hypothesis concerning the involvement of astrocyte dsysfunction in HD.   
 
1.4. Bioenergetics 
  In humans, the brain is the organ with the highest energy demand.  It represents  
only 2% of total body mass and yet, at rest, uses 25% of body glucose and 20% of 
total body oxygen (Magistretti et al. 2002).  Astrocytes are intimately involved in 
brain energetics by transporting glucose, as a source of brain glycogen (Wender, 
Brown et al. 2000) and they are the origin of most brain glycolysis, which serves to 
supply neurons with lactate (Pellerin 2005).  Neurons account for most of the brain’s 
energy expenditure (85-95%) (Attwell and Laughlin 2001; Rothman, Behar et al. 
2003) and in the absence of that energy, even for brief periods, they die (Moreira, 
Santos et al. 2007).  Energetic deficits are involved in most of the major protein 
misfolding disorders.  Positron emission tomography (PET) studies of AD patients 
indicate a reduced glucose uptake, compared with controls (Silverman, Small et al. 
2001), and a decreased glucose use that correlates with cognitive decline (Messier and 
Gagnon 1996).  In AD, and related disorders, hyperphosphorylation of tau is a crucial 
contributor to disease progress through a variety of mechanisms.  This tau 
abnormality correlates closely with a decrease in brain glucose transporters and the 
downregulation of the transcription factor that controls them (Liu, Liu et al. 2008).  
One of these transporters, glucose transporter 1 (GLUT1) is expressed in all brain 
cells, including astrocytes (Magistretti and Pellerin 1996).  In the AD brain, there 
appears to be a significant increase, in the expression and activity of glycolytic 
enzymes, including phosphofructokinase, pyruvate kinase, hexokinase and glucose 6-
phosphate dehydrogenase. Furthermore, the increase in glucose 6-phosphate 
dehydrogenase activity appears to correlate with an increase in astrocyte GFAP (Bigl, 
Bruckner et al. 1999).  Possibly, an increase in astrocytic glycolysis is a 
compensatory mechanism.  This notion is supported by Arias, Montiel et al. (2002), 
who showed, in a rat model of AD, that inhibition of glycolysis, by idoacetate, results 
in greater hippocampal Aβ neurotoxicity. In that study synapses appeared to be 
especially vulnerable to metabolic disturbance.  Astrocytes are the primary source of 
brain glycogen, which can be mobilized during neuronal activity, injury or 
hypoglycemia.  Astrocytic glycogen concentrations are also known to be highest near 
areas of high synaptic density and can be modulated by neurotransmitters (Phelps 
1972; Brown and Ransom 2007).  In the AD brain, the glycogen synthesis pathway 
may be impaired. Huang, Hollingsworth et al. (2004) showed that, in the AD brain, 
there is an accumulation of high molecular weight amylose, an unbranched glucose  
polymer, that cannot be broken down by the brain back into glucose.  Amylose is part 
of the biosynthetic pathway of glycogen and its accumulation points to a fault in that 
pathway and hence some, as of yet unexplored, astrocyte dysfunction. 
 
  Bioenergetic abnormalities also appear to play a key role in ALS.  PET studies 
of ALS patients show a progressive decrease in metabolism in brain motor regions 
(Hatazawa, Brooks et al. 1988).  Glucose transport is impaired in the synaptic 
terminals of Cu/Zn-SOD1 mice, a transgenic model of ALS (Guo, Kindy et al. 2000) 
and, to some degree, there is a downregulation of GLUT1 in these mice (Garbuzova-
Davis, Saporta et al. 2007).   Bioenergetic defects and impaired glucose utilization 
precede neurodegeneration in the SOD1 mouse model (Browne, Yang et al. 2006). 
Similar metabolic deficits are seen in HD.  There is a reduced glucose metabolism in 
the cortex and basal ganglia of HD patients, as shown by PET studies (Andrews and 
Brooks 1998; Powers, Videen et al. 2007), and metabolic deficits correlate closely 
with behavioural and motile impairments.  Nuclear magnetic resonance studies 
suggest that there may be an elevated lactate production in the HD brain and hence, 
possibly, a defect in glycolysis (Jenkins, Koroshetz et al. 1993; Jenkins, Rosas et al. 
1998).  Mutant huntingtin binds to glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH), a key glycolytic enzyme in vitro, and GAPDH activity is decreased in HD 
(Burke, Enghild et al. 1996; Kish, Lopes-Cendes et al. 1998).  However, a more 
recent study suggests that glycolytic activity increases in one model of HD, perhaps 
as a mechanism to compensate for impaired neuronal mitochondrial function (Olah, 
Klivenyi et al. 2008).  PET studies also show a reduced cerebral glucose metabolism 
in Parkinson’s patients that correlates with disability (Berding, Odin et al. 2001). In 
the PD brain (Henchcliffe, Shungu et al. 2008) and in one mouse model, there is some 
evidence of impaired glycolysis,  as well as mitochondrial dysfunction (Mazzio, 
Reams et al. 2004).  Finally, in prion disease, there is one study that shows decreased 
GLUT1 expression in the microvascular endothelium of scrapie- infected 
hyperglycemic mice (Vorbrodt, Dobrogowska et al. 2001).  Overall, there is 
considerable evidence to indicate a central role for astrocytes in brain energy 
metabolism (Pellerin 2005; Pellerin, Bouzier-Sore et al. 2007) and there are clear 
indications that perturbation in brain bioenergetics contributes to neurodegeneration.   
Yet, there are very few studies that examine how the presence of intra- or 
extracellular misfolded protein directly affects the ability of astrocytes to carry out 
their energetic functions.  
 
1.5. Calcium Signalling and Cerebral Blood Flow 
  Astrocytes are part of a ‘neurovascular unit,’ along with blood vessel 
endothelial cells and neurons that serve to tightly couple blood flow to neuronal 
activity.  Astrocyte endfeet extensively ensheath cerebral microvessels, whilst other 
processes from the same astrocytes surround multiple neuronal synapses.  Several 
recent papers suggest that astrocytes play a crucial regulatory role in the transfer of 
information between neurons and microcirculation (Zonta, Angulo et al. 2003; 
Takano, Tian et al. 2006; Schummers, Yu et al. 2008).  This is thought to primarily 
occur through the following physiological mechanism:  (1) Increased synaptic 
glutamate is detected by astrocytic mGluR’s, which results in an increase of their 
Ca
2+.  Astrocytes have a syncytial gap junction network through which such Ca
2+ 
signals can propagate (Kuo, Chan-Ling et al. 2008).  (2) Intracellular calcium 
increase, via an Inositol triphosphate/Phospholipases A2 signalling pathway, activates 
 
Fig 1. Astrocytes couple glucose transport and utilization to synaptic activity.  Astrocyte 
endfeet expressing the glucose transporter GLUT-1 surround all brain capilleries.  The same 
astrocytes have processes near to synapses.  It’s thought that astrocytes uptake glucose from 
blood vessels to supply functioning neurons with energy in the form of lactate.  Figure from 
Pellerin 2005. 
  
cyclooxygenase-1, an enzyme that converts arachidonic acid into prostaglandin H2, 
which is a precursor to prostaglandin, a vasodilator.  (3) Prostaglandin is released and 
microvessels dilate (Iadecola and Nedergaard 2007; Koehler, Roman et al. 2009).   
 
  The reviews cited above also cover several other astrocyte-mediated 
vasoregulatory pathways, some of which may result in astrocyte-induced 
vasoconstriction.  A dysregulation or reduction of cerebral blood flow has been noted 
in AD (Lange-Asschenfeldt and Kojda 2008), ALS with dementia (Ishikawa, Morita 
et al. 2007), PD (Jellinger and Attems 2006) and HD (Deckel and Cohen 2000; 
Deckel, Volmer et al. 2000).  Furthermore, one study showed a close correlation 
between astrocyte loss and cerebral blood flow decrease in frontotemporal dementia 
(Martin, Craft et al. 2001).  Given the importance of astrocytes within the 
neurovascular unit, perhaps they are involved in these observed alterations of cerebral 
blood flow.  Indeed, one recent AD study provides support for this notion: Takano, 
Han et al. (2007) showed, in three different mouse models of AD, abnormal 
spontaneous astrocyte Ca
2+ signalling that led to oscillatory cycles of constriction and 
relaxation in microvessels.  Aβ administration increased the frequency of these Ca
2+ 
transients. Recently, Kuchibhotla, Lattarulo et al. (2009) demonstrated that, in a 
mouse model of AD, there was an increased resting level of  intracellular astrocytic 
calcium, a frequent set of synchronous spontaneous calcium signals across the 
astrocyte network and more intense infrequent calcium waves close to Aβ deposits.  
Another paper (Chow, Yu et al. 2009) shows that, in vitro, low concentrations of Aβ 
alone can cause spontaneous intracellular calcium waves, as well as more transient 
changes in calcium concentration, within the astrocytes. The same paper showed an 
increase in GFAP and S100β immunocytochemical staining.  So far, although 
alterations in cerebral blood flow have been seen in a number of neurodegenerative 
diseases, as described above, only in AD has anyone observed alterations in astrocyte 
calcium concentrations or signalling.  
 
1.6. Inflammation 
  Astrocytes actively participate in the inflammation that occurs as part of most 
protein misfolding disorders.  The glial cells primarily involved in inflammation are  
microglia.  These cells are of the macrophage/monocyte lineage and are activated in 
response to injury, infection or inflammation.  They are phagocytic cells that release 
numerous cytokines and other inflammatory molecules (Hanisch 2002; Streit 2002) . 
In response to pathology, astrocytes also change in morphology, increase their 
expression of structural filaments such as glial fibrillary acidic protein (GFAP), 
vimentin and nestin and can express a variety of proinflammatory, anti-inflammatory, 
neuroprotective molecules and neurotoxic molecules (See Table 1).  This is known as 
‘astrocyte activation.’  Activated astrocytes tend to proliferate in a manner known as 
‘astrogliosis’ and have a number of beneficial or detrimental effects.  Astrocytes can 
be activated in vitro with ciliary neurotrophic factor (CNTF) and this causes them to 
post-transcriptionally modify their glutamate transporters in ways that, in vivo, has 
been demonstrated to significantly improve glutamate uptake (Escartin, Brouillet et 
al. 2006).  However, in some disease conditions, reactive astrocytes can also 
downregulate EAAT2 (Barbeito, Pehar et al. 2004).  Astrocytes can also be activated 
by the cytokines IL-6, interleukin and tumour necrosis factor alpha, released by 
microglia, and other immune cells.  Activation can lead to an enhancement of 
astrocytic glycolysis and a mobilization of their glycogen stores (Gavillet, Allaman et 
al. 2008).  CNTF- activated astrocytes express an entirely new set of metabolic 
enzymes that allows them to utilize ketones and fatty acids to provide themselves and 
possibly neurons with additional energy (Escartin, Pierre et al. 2007; Gavillet, 
Allaman et al. 2008).   Smits, van Beelen et al. (2001) showed that reactive astrocytes 
can interfere directly with the binding of misfolded protein, in this case Aβ, to 
microglia.  However, oxidative stress caused by reactive astrocytes, from such 
sources as inducible NO synthase, may well outweigh all of their neuroprotective 
effects (Hewett, Csernansky et al. 1994; Chao, Hu et al. 1996; Cassina, Peluffo et al. 
2002).  In a resting state, astrocytes are organized into non-overlapping spatial 
domains and are interconnected via connexin-43 gap junctions.  In an activated state 
they start to overlap and they lose their gap junction connectivity.  This loss of 
connectivity may limit the spread of toxic factors, but may also decrease the ability of 
astrocytes to engage in their normal homeostatic functions (Kielian 2008) .  
Curiously, misfolded protein has been demonstrated to directly interfere with the 
production of a neuroprotective chemokine, RANTES (see Table 1) in a mouse model  
of HD (Chou, Weng et al. 2008).  One paper also demonstrated that oxidative damage 
and mitochondrial dysfunction in astrocytes can lead to them producing less Glial cell 
line Derived Neurotrophic Factor (GDNF), a neurotrophin that can protect neurons 
from apoptosis (McNaught and Jenner 2000).   
 
Table 1. Some of the factors released/upregulated by activated astrocytes. 
Factor  Reference(s)  Notes 
Proinflammatory     
Interleukin-6 (IL-6)  (Gadient and Otten 1997; 
Wang, Asensio et al. 
2002) 
(Klegeris, Giasson et al. 
2006), 
Klergis paper states that 
IL-6 and ICAM1 are 
strongly induced by the 
presence of α-synuclein, 
the PD misfolded protein 
Interleukin-1β   (Hu, Akama et al. 
1998),(Moynagh 2005) 
(Gavillet, Allaman et al. 
2008) 
Key inducer of 
inflammation in Astros.   
Inter-Cellular Adhesion 
Molecule 1 (ICAM1) 
(Klegeris, Giasson et al. 
2006), 
Involved in transmigration 
of immune cells across the 
blood brain barrier 
Monocyte Chemoattractant 
protein 1 
(Baron, Bussini et al. 
2005; Huang, Wujek et al. 
2005) 
Also involved in 
recruitment of peripheral 
immune cells to the brain 
Tumor Necrosis Factor-α  (Leng, Mura et al. 2005)   
Antinflammatory     
Transforming Growth 
factor β1 
(Dhandapani, Hadman et 
al. 2003),  
Also neuroprotective 
Interleukin-10  (Pousset, Cremona et al. 
1999) 
 
Neuroprotective      
Fibroblast Growth Factor-
2 
(Albrecht, Dahl et al. 
2002),  
Can stimulate astrocytes to 
become reactive 
Nerve Growth Factor  (Pehar, Vargas et al. 2005)  Also neurotoxic. Can 
cause apoptosis in neurons 
expressing p75 receptor 
Glial Cell Line Derived 
Neurotrophic Factor 
(McNaught and Jenner 
2000; Tanaka, Oh-Hashi et 
al. 2008) 
Mitochondrial dysfunction 
or reduced glutathione, 
seen in PD, may reduce 
the expression of this 
factor. 
Brain Derived 
Neurotrophic Factor 
(BDNF) 
(Kimura, Takahashi et al. 
2006) 
  
Regulated on Activation, 
Normal T-cell Expressed 
and Secreted (RANTES or 
CCL5 
(Chou, Weng et al. 2008; 
Tripathy, 
Thirumangalakudi et al. 
2008) 
Upregulated in AD, 
suppressed in HD 
Various antioxidants  See oxidative stress 
paragraph 
 
Neurotoxic     
Inducible NO Synthase  (Cassina, Peluffo et al. 
2002) 
Creates NO, causes 
oxidative stress. 
Calcium Binding Protein 
S100β 
(Petzold, Jenkins et al. 
2003), (Donato 2001) 
Mostly thought of as 
neurotoxic in 
neurodegenerative 
disorders.  Neurotrophic at 
very low concentrations.  
Cyclooxygenase-2  (Consilvio, Vincent et al. 
2004) 
 
Other     
Cililary NeuroTrophic 
Factor (CNTF) 
(Escartin, Brouillet et al. 
2006 
Activates astrocytes 
 
1.7. Oxidative Stress 
  Oxidative stress is involved in the pathology of most, if not all, 
neurodegenerative disorders (Andersen 2004; Emerit, Edeas et al. 2004). 
The generation of radicals, molecules that carry one or more unpaired electrons, is an 
integral feature of normal cellular function.  Radicals have the potential to damage 
any cellular component they interact with.  Reactive oxygen and nitrogen species 
(ROS and RNS) are the most common biological radicals.  Oxidative stress results 
from imbalance between the production of ROS and cellular antioxidant capacity. 
Under pathological conditions, astrocytes can potentially act both as a source of 
oxidative stress and as a producer of neuroprotective antioxidants.  They are also, 
though to a lesser degree than neurons, vulnerable to oxidative stress (Rohrdanz, 
Schmuck et al. 2001).  Activated astrocytes upregulate inducible nitric oxide synthase 
(iNOS) and release high levels of nitric oxide in vitro, which can damage neurons 
(Hu, Akama et al. 1998; Cassina, Peluffo et al. 2002).  In vivo, astrocytic iNOS 
induction has been shown in progressive supranuclear palsy (Komori, Shibata et al. 
1998), scrapie infected mice (Ju, Park et al. 1998) and in MS patients (Calabrese, 
Scapagnini et al. 2003).   However, astrocytes contain high levels of glutathione, 
glutathione transferase, catalase and superoxide dismutase (Makar, Nedergaard et al. 
1994; Dringen, Gutterer et al. 2000; Power, Asad et al. 2008) which also make them  
able to protect neurons from ROS (Desagher, Glowinski et al. 1996).  Depending on 
the disease and condition, astrocytes are reported to have additional oxidative stress 
inducing or protective mechanisms.  In AD, PD and ALS, Peroxiredoxin 6 is 
upregulated in astrocytes near neurons immmunopositive for tau (Power, Asad et al. 
2008), α-synuclein (Power, Shannon et al. 2002) or SOD1 (Strey, Spellman et al. 
2004).  Astrocytic monoamine oxidase is increased in AD and PD, which leads to 
H2O2 and NO production, as well as mitochondrial dysfunction, and neuronal death 
(Girgin Sagin, Sozmen et al. 2004; Mallajosyula, Kaur et al. 2008).  In several models 
of ALS, astrocytes appear to be more neurotoxic than neuroprotective due to 
oxidative stress (Bilsland, Nirmalananthan et al. 2008; Cassina, Cassina et al. 2008; 
Marchetto, Muotri et al. 2008).  In all the ALS studies the mutated form of superoxide 
dismutase 1, SOD1
G93A (responsible for familial ALS) was expressed in astrocytes 
and showed that they were toxic towards co-cultured neurons.  The latter two papers 
showed that this toxicity was ablated with the addition of antioxidants to the culture.  
Bilsland, Nirmalananthan et al. (2008) demonstrated that SOD1
G93A/astrocytes induce 
mitochondrial dysfunction in the co-cultured neurons.  The neurotoxicity of these 
astrocytes can also be reversed, by overexpressing the transcription factor Nrf2, 
responsible for glutathione production (Vargas, Johnson et al. 2008).  Heme oxidase-
1(HO-1) is an inducible rate-limiting enzyme in the degradation pathway of heme to 
biliverdin, carbon monoxide and iron and in AD, PD and ALS, it is highly expressed 
in astrocytes surrounding sites of neurodegeneration (Schipper 2000; Pehar, Vargas et 
al. 2005).  The products of heme breakdown are involved in both neuroprotection and 
neurotoxicity.  Two recent PD papers, however, suggest that the oxidative damage, 
caused by astrocytic HO-1, outweighs any neuroprotective effects (Song, Su et al. 
2006; Song, Song et al. 2007).  Oxidative stress also has a direct effect on astrocytes.   
 
  EAAT2 loss is reported to be directly caused by the presence of ROS in both 
ALS transgenic mice and Aβ treated cell cultures (Gibb, Boston-Howes et al. 2007; 
Matos, Augusto et al. 2008).  In the transgenic mice (Gibb, Boston-Howes et al. 
2007) mutant SOD1 proteins, exposed to oxidative stress, trigger a caspase-3 cleavage 
of EAAT2 and so inhibit it.  Subsequently, one fragment of cleaved EAAT2 is 
sumoylated and directed towards a subnuclear structure known as promyelocytic  
nuclear bodies (PML-NBs) which increase  infrequency during the progression of 
ALS. Though this has yet to be established, the authors of this paper postulate that the 
accumulation of PML-NBs may interfere with astrocyte nuclear function.  Matos, 
Augusto et al. (2008) showed that the presence of Aβ-inhibited astrocytic glutamate 
uptake of these cells, as directly measured using d-[
3H]aspartate, demonstrated a 
decrease in GLT-1 transporter levels via western blotting.  They then showed the 
presence of protein and lipid oxidation in the presence of Aβ1-40.  One previous 
report showed that lipid oxidation can cause 4-hydroxy-2-nonenal to form, which co-
immunoprecipitates with GLT-1 in Aβ treated cells and may affect its function 
(Lauderback, Hackett et al. 2001).  
 
1.8. Models of Protein Misfolding  
In studying protein misfolding disorders, there are a number of potential 
proteins that could be used: primarily α-synuclein, PrP
C, SOD1, Aβ, tau and 
huntingtin. Extracellular misfolded protein is less practical than a genetic model of 
intracellular misfolded protein, if one wishes to employ a stem cell 
differentiation/microarray approach, as described in my future directions.  This 
eliminates Aβ and PrPC as useful models for this experimental purpose.  Mutated tau 
and α-synuclein are both options but there is a great deal of literature on SOD1 and, 
as such, designing original experiments might be difficult.  Also, the SOD1 mutation 
is only representative of a small proportion of total ALS cases (Valdmanis and 
Rouleau 2008).  Huntingtin polyglutamine misfolding and aggregation is, hence, my 
model of choice.  As a genetic disease it’s amenable to manipulation by molecular 
biology.  Furthermore, in HD there is a threshold effect whereby below a certain 
number of glutamine repeats (∼36, as described below) there is no obvious disease 
phenotype, whereas above that repeat length, HD is evident (Williams and Paulson 
2008).   This threshold effect also appears in cell cultures (e.g. (Huang, Schiefer et al. 
2008)  and mouse models (Kuhn, Goldstein et al. 2007). This provides the internal 
control, in which cells with low CAG repeats can be compared with those with high 
repeats, so that one knows that any toxicity is due to the misfolding and not some 
other aspect of the huntingtin protein.  Furthermore, it is encouraging to note that the  
expression profiles of many different mouse models closely correlate with the gene 
expression signature seen in human brain HD tissue (Kuhn, Goldstein et al. 2007). 
 
1.9. Huntington’s disease 
HD is an autosomal, dominant, neurodegenerative disorder characterized by 
movement disorders, psychiatric disturbances and cognitive deficits.  The motor 
problems begin subtly, as minor involuntary movements, gradually progressing until 
the whole body is consumed in chorea, leading to death, in 15-20 years after onset, or 
7-10 years in the juvenile form (Gusella and MacDonald 1995).  The number of 
glutamines accounts for about 60% of the variation in the age of disease onset, with 
the rest accounted for by environment and other genes (Rosenblatt, Brinkman et al. 
2001; Wexler, Lorimer et al. 2004).  Unaffected individuals have 35 or less CAG 
repeats.  Those with 36-40 repeats have some likelihood of getting HD, with those at 
around 36 repeats only occasionally exhibiting symptoms and only a very few that are 
free from disease at 40, whereas those, with more than 40 repeats, always do.  All 
polyglutamine repeat disorders have a similar relationship between age of onset and 
CAG repeat length (fig. 2.). 
 
Fig 2.  Relationship between age of onset and polyglutamine repeats in 
different genetic diseases Figure from (Gusella and MacDonald 2000). 
  
   The primary neuropathological feature of HD is a selective loss of neurons in 
the cortex and striatum. Towards the end of the disease, the pathology becomes more 
diffuse and the hippocampus, cerebellum, amygdala, some thalamic nuclei and other 
brain regions suffer loss of neurons.  Medium-sized spiny neurons, in the striata that 
innervate the globus pallidus, are the most susceptible (Li and Li 2004). 
 
HD is caused by an abnormal polyglutamine expansion repeat near the amino 
terminal of the huntingtin protein (1993).  Genetically this corresponds to repeat of 
the codon CAG in exon-1 of the gene that encodes htt (IT-15), located on the short 
arm of chromosome 4.  In those with HD, there is also an increase in cytoplasmic and 
nuclear inclusions of mutant huntingtin (Davies, Turmaine et al. 1997), which is 
apparent in presymptomatic patients (Gomez-Tortosa, MacDonald et al. 2001).  
However, there is good evidence that inclusions do not predict cell dysfunction or 
disease activity, which, instead, seems to correspond to the presence of low molecular 
weight intermediate oligomers (Mukai, Isagawa et al. 2005).  The mechanism, by 
which misfolded htt leads to neuronal dysfunction and loss, has yet to be elucidated, 
but a number of key features have been identified.  The initial stages appear to 
involve the aggregation of htt into oligomers, trimers and dimers, as well as abnormal 
proteolysis which facilitates this aggregation (Wellington, Leavitt et al. 2000).  The 
formation of these aggregates and the production of mutant huntingtin is thought to 
eventually overcome the ability of the proteosome or autophagic vacuolisation to 
degrade them, leading to an unmanageable cellular load of aggregate proteins 
(Rangone, Humbert et al. 2004).  This misfolded protein and its aggregates bind to, 
and interfere with, proteins that regulate cellular bioenergetics (Panov, Burke et al. 
2003; Browne and Beal 2004), neurotransmitter release (Modregger, DiProspero et al. 
2002; DiProspero, Chen et al. 2004), apoptosis (Hickey and Chesselet 2003) and 
transcription (Cha 2000), amongst others.  Mutant huntingtin also appears to interfere 
with the function of wild-type huntingtin (Busch, Engemann et al. 2003; Zuccato, 
Liber et al. 2005). 
 
  Cells die in HD, partly through apoptosis, a tightly regulated cascade of 
biochemical events involving the activation of cystein proteases called caspases,  
changes in nuclear morphology, DNA fragmentation, cytoplasmic shrinking, 
membrane blebbing, reversal of orientation and the release of mitochondrial death 
factors (Friedlander 2003).  Improper apoptosis has been associated with several 
neurodegenerative diseases, including HD (Petersen, Mani et al. 1999).  DNA 
fragmentation, indicative of apoptosis, is present in the brain of HD patients, as are a 
number of apoptotic proteins that are abnormally activated/changed including Bax, 
Bcl-2, Poly (ADP-ribose), polymerase (PARP), Caspase-1, Calpain, Caspase-8 and 
Caspase-3 (Ona, Li et al. 1999; Vis, Schipper et al. 2005; Teles, Rosenstock et al. 
2008).  Caspase-3 is a key protease in apoptosis and htt is one of its substrates 
(Goldberg, Nicholson et al. 1996).  Mouse research has shown that htt is cleaved by 
apoptotic caspases, at amino acid site 552, and that caspase-mediated cleavage may 
lead to neurodegeneration.  In a YAC transgenic mouse model of HD, Wellington, 
Ellerby et al. (2002) showed that caspase activation and htt cleavage preceded the 
onset of HD-like symptoms.  Futhermore, the inhibition of caspase-1 activity by a 
drug, called minocycline, in HD mice, slowed neurodegeneration and these mice lived 
14% longer than those that were not treated with minocycline (Berger 2000).  Part of 
the apoptosis seen in HD may also be due to a loss of wild-type htt anti-apoptotic 
function.  Mice, without htt, show extensive embryonic cell death (Zeitlin, Liu et al. 
1995) and, on the other hand, striatal cells, in which wt-htt is overexpressed, die less 
when deprived of serum or treated with NP-3 (Rigamonti, Sipione et al. 2001). 
Mitochondria play a central role in the apoptotic pathway and htt is known to cause 
mitochondrial dysfunction as described in more detail below (Bossy-Wetzel, Petrilli 
et al. 2008).  This dysfunction can lead to the release of pro-apoptotic factors, such as 
cytochrome c, from mitochondria.   
 
1.10. Huntingtin and Transcriptional Dysregulation 
  The primary site of mutant huntingtin toxicity has been suggested to be the 
nucleus. N-terminal fragments of htt are found in nuclear aggregates (DiFiglia, Sapp 
et al. 1997). Blocking the nuclear entry of mutant htt, in a primary cell culture of HD 
(Saudou, Finkbeiner et al. 1998), lessens its apoptotic effects, whereas adding a 
nuclear localization signal to htt increases phenotypic severity (Peters, Nucifora et al. 
1999).  This nuclear pathology is likely to be largely due to transcriptional  
dysregulation and the abnormal interaction of mutant htt with transcription factors 
(Cha 2000; Sugars and Rubinsztein 2003; Li and Li 2004; Cornett, Smith et al. 2006).  
This dysregulation results, in turn, in altered mRNA expression levels in cell models, 
and in the transgenic mouse and HD human brain (Cha 2000; Luthi-Carter, Strand et 
al. 2002).  Htt interacts with the following transcriptional regulators: specificity 
protein 1 (sp1) (Qiu, Norflus et al. 2006), TATA-box binding protein associated 
factor II, 130kda (TAFII130) (Dunah, Jeong et al. 2002), repressor element 1-
silencint transcription factor (REST) (Zuccato, Ciammola et al. 2001), p53 and cyclic 
Adenosine MonoPhosphate (cAMP) response element binding protein (Steffan, 
Kazantsev et al. 2000). REST is a transcription factor of particular note, as it is 
involved in the transcription of Brain Derived Neurotrophic Factor (BDNF), a 
neurotrophin that supports the survival of the spiny striatal neurons that are lost in HD 
(Zuccato, Belyaev et al. 2007; Sanchez, Xu et al. 1999; Gafni and Ellerby 2002). 
 
1.11. Huntingtin Cleavage 
  There is strong evidence to support the notion that the toxic protein in HD is not 
full-length htt but, rather, an N-terminal fragment.  Although the htt gene (IT-15)  
encodes a 3,500 aa protein, the expression of its exon-1, is sufficient to reproduce 
much of HD pathology, both in cell and animal models (Davies, Turmaine et al. 1997; 
Hackam, Singaraja et al. 1998; Schilling, Becher et al. 1999).  The N-terminal 
fragment is the main component of the nuclear inclusions, seen in HD, and antibodies 
raised against more c-terminal parts of htt cannot detect these inclusions (Hackam, 
Singaraja et al. 1998).  These fragments aggregate more readily than full-length htt in 
cell models and in vitro (Li and Li 1998)  and seem to be more toxic (Lunkes, 
Lindenberg et al. 2002; Ratovitski, Gucek et al. 2009). The human htt protein 
contains cleavage sites for calpain, caspase-6 and caspase-3 (Wellington, Ellerby et 
al. 1998; Wellington, Singaraja et al. 2000; Gafni and Ellerby 2002) and prevention 
of htt cleavage at the caspase-6 sites in a YAC transgenic mouse model is 
neuroprotective (Graham, Deng et al. 2006).  Also, in this YAC transgenic mouse 
model, Wellington, Ellerby et al. (2002) showed that caspase activation and htt 
cleavage preceded the onset of HD-like symptoms.  Furthermore, caspase inhibition 
attenuates cell death caused by mutant huntingtin in cultured cells (Kim, Lee et al.  
1999; Wang, Mitsui et al. 1999).  All of this points to the necessity of caspase 
cleavage of htt for HD pathogenesis and also points towards the potential of caspase 
inhibition as a therapeutic strategy. 
 
1.12. The ubiquitin-proteosome  system  and autophagy: a role in HD 
  The ubiquitin-proteosome system (UPS) is a multi-subunit protease assembly 
responsible for regulating the concentration of various short-lived, damaged or 
misfolded cellular protein. The UPS functions via two successive processes.  First, 
proteins are covalently conjugated to multiple molecules of ubiquitin and then tagged 
proteins are degraded by the 26S preosome or via autophagy (Ciechanover 1998). 
This process is impaired in HD.  Bennett, Bence et al. 2005 modified cells expressing 
htt exon-1, with a florescent reporter, which accumulates when the proteosome is 
inhibited.  In cells with a plasmid expressing Q103 htt exon-1, these cells fluoresced 
brightly, whilst the Q25 exon-1 transfected cells did not.  UPS function has also been 
shown to be inhibited in a number of other cell models of HD and the synapses of 
neurons cultured from R6/2 mice (Wang, Wang et al. 2008).  Evidence for UPS 
inhibition has also been seen in HD post-mortem brain tissue (Seo, Sonntag et al. 
2004; Bennett, Shaler et al. 2007).  Antibodies against ubiquitin and proteosome 
subunits label polyglutamine aggregates in cell models, mouse brains and the HD 
postmortem brain, suggesting that this may be due to a change in the subcellular 
localization or the sequesteration of UPS components (Davies, Turmaine et al. 1997; 
DiFiglia, Sapp et al. 1997).  However, UPS inhibition is also seen in cell models in 
the absence of visible aggregates.  Indeed, one paper implies that the formation of 
inclusion bodies within neurons improves htt degradation (Mitra, Tsvetkov et al. 
2009).  One more recent theory is that misfolded portions of htt may block the 26S 
proteosome, as it does not easily degrade those proteins.  Purified fibrillar species of 
htt, from both the HD brain and transgenic mouse models, have been shown to 
decrease proteosome activity in vitro (Diaz-Hernandez, Valera et al. 2006).  However, 
the evidence for UPS impairment in HD and HD models is equivocal.  Maynard, 
Bottcher et al. (2009) and Bett, Cook et al. (2009)  both showed that whilst there was 
an accumulation of ubiquinated proteins in transgenic HD mice, there was no UPS 
impairment.  Other groups also show no UPS impairment (Bowman, Yoo et al. 2005;  
Ding, Lewis et al. 2002) or even an increase in UPS activity (Diaz-Hernandez, 
Hernandez et al. 2003; Bett, Goellner et al. 2006).  Further research will hopefully 
resolve this controversy. 
 
  Huntingtin may be degraded by the autophagic-lysosomal system, in which 
proteins are sequestered into autophagosomes which then fuse with lysosomes full of 
acidic proteases (Sarkar and Rubinsztein 2008).  Increased autophagy has been seen 
in cell (Ravikumar, Duden et al. 2002) and mouse models of HD (Davies, Turmaine 
et al. 1997) as well as postmortem HD brain (Sapp, Schwarz et al. 1997).  Also, in 
HD cell models, inhibition of autophagy either by preventing autophagosome 
formation or by autophagsome-lysosome fusion, results in an increased build-up of 
aggregated and soluble mutant htt (Seglen and Gordon 1982; Ravikumar, Duden et al. 
2002).  Mutant htt appears to be preferentially degraded by autophagy over wild-type 
htt (Sarkar, Ravikumar et al. 2009).  The protein ‘mamalian target of rapamycin’ 
(mTOR) is a key negative regulator of autophagy. mTOR is sequestered in mhtt 
aggregates in HD and HD models which causes an induction of autophagy and an 
increased clearance of mutant htt (Sarkar, Ravikumar et al. 2009).    
 
1.13. Huntingtin, Mitochondria and oxidative stress 
  Around 50% of pre-symptomatic HD patients exhibit metabolic defects some 
years before disease onset (Antonini, Leenders et al. 1996).  As well as the defects in 
glycolysis, there appear to be defects in the TCA cycle and oxidative phosphorylation 
in the HD brain (Browne and Beal 2004).  Several of the electron transport chain 
complexes (II, III, IV) have a marked reduction in activity in the late stages of HD 
(Gu, Gash et al. 1996; Browne, Bowling et al. 1997), although there do not appear to 
be any changes in these in the early stage or in presymptomatic HD patients (Tabrizi, 
Cleeter et al. 1999; Guidetti, Charles et al. 2001).  However, the activity of aconitase, 
the enzyme that catalyses the breakdown of citric acid in the TCA cycle, is reduced 
by 52% in the cerebral cortex, 27% in the putamen and by 8% in the HD caudate 
(Tabrizi, Cleeter et al. 1999).  Mitochondrial dysfunction is also apparent in mouse 
models of HD: R6/2 mice show a dramatic decrease in aconitase activity, as well as a 
reduction in complex IV activity, in both striatum and cortex. Also, in R6/2 mice, this  
complex IV deficiency precedes neuronal death and may well be a reason for it 
(Tabrizi, Workman et al. 2000).  In one cell model of HD, striatal neuron cell 
cultures, derived from a knock-in mouse expressing htt containing 111 glutamines, 
showed significantly impaired ATP production and mitochondrial respiration 
compared with control cells(Milakovic and Johnson 2005).  In another cell model of 
HD, there is an inverse relationship between CAG repeat length and the intracellular 
ratio between ATP and ADP (Seong, Ivanova et al. 2005).  There also appear to be 
defects in the ability of mitochondria from HD patients to handle calcium: 
mitochondria from HD patient lymphoblasts have a lower transmembrane potential 
and tend to depolarize at lower calcium concentrations, as compared to healthy 
controls (Panov, Gutekunst et al. 2002).  The Permeability Transition Pore (PTP) 
mediates mitochondrial swelling and if it remains open for a long time, usually due to 
apoptotic challenges, caspases are released into the cytosol and cell death is initiated 
(Szalai, Krishnamurthy et al. 1999).  In isolated mitochondria and in mutant htt 
expressing cells htt induces PTP opening (Lim, Fedrizzi et al. 2008).  
 
   Mice expressing full-length htt seem to have similar dysfunctions (Panov, 
Gutekunst et al. 2002) and mitochondria from cells expressing mutant htt have a 
reduced ability to uptake calcium as compared with wild-type cells (Quintanilla, Jin et 
al. 2008).  These mitochondrial impairments appear to stem both from the 
transcriptional dysregulation of key mitochondrial enzymes (Bae, Xu et al. 2005; Cui, 
Jeong et al. 2006; Oliveira, Chen et al. 2006), as a direct interaction of htt with 
mitochondria (Choo, Johnson et al. 2004; Orr, Li et al. 2008), and a disruption of the 
trafficking of mitochondria within neurons.          
 
  The HD striatum and cortex are immunopositive for oxidatively damaged 
products (Browne, Bowling et al. 1997; Polidori, Mecocci et al. 1999).  A marker of 
oxidative stress, 8-hydroxy-2-deoxyguanosine (OH
8dG), is significantly increased in 
the HD caudate (Browne, Bowling et al. 1997) and in R6/2 mice (Stack, Kubilus et al. 
2005).  R6/2 mice also show increased lipid peroxidation and elevated levels of 
several oxidative stress markers (Browne and Beal 2006). DNA strand breaks are 
related to free radical damage and increased DNA fragmentation correlates with CAG  
repeat length (Driggers, Holmquist et al. 1997; Browne, Ferrante et al. 1999). 
 
1.14. Astrocytes and HD 
  As described in section 1.3, the Li lab has demonstrated that the expression of 
mutant htt in astrocytes alone, in a mouse, produces neurological deficits.  They also 
showed that part of this phenotype can be explained by the inhibition of the 
transcription factor SP-l, which is responsible for the expression of the glial glutamate 
transporter GLT-1.  This is based on their previous cell culture work (Shin, Fang et al. 
2005). Chou, S. Y., J. Y. Weng, et al. (2008) have also shown that the expression of 
htt in astrocytes lessens the production of a key chemokine CCL/RANTES (see 
section 1.6.).  Beyond these two reports no other studies have been carried out that 
test the involvement of astrocytes in HD, but astrocytes are involved in the pathology 
of a number of other neurological diseases as described in this introduction.  Also, 
there is a fair amount of literature from studies on aspects of HD pathology that 
implicate astrocyte involvement (see sections 1.4-1.7.).  Hence, it would be rational to 
carry out an extensive study of astrocyte biology, within HD.  
 
2. Aims  
  The aim of this work was to establish and characterise a mouse astrocyte cell 
culture system with high purity and lay out some groundwork for future experiments 
relating to a functional assay (calcium wave propagation).  Furthermore, I tested 
whether expression of httEx1, with a polyglutamine expansion, leads to loss of GLT-1 
expression.   
 
3. Materials and Methods 
3.1.  Tissue Culture 
3.1.1. Primary Mouse Astrocyte Culture 
P0 mouse pup were sacrificed by decapitation.  All procedures were carried 
out under Dr. Wyttenbach’s animal project license.  I was the holder of a personal 
license.  The cortices were dissected and the hippocampus and meninges were 
removed.  The cortices were cut into <1mm
3 cubes and suspended in 5mL of  DMEM 
per two corticies (Sigma, UK) (2-5 brains).  They were then vortexed for 90 seconds  
in a 50mL centrifuge tube (Greiner Bio One) and the suspension was sieved through a 
40µm cell strainer (BD Falcon) and seeded in a T75 flask containing astrocyte 
medium.  In all but my first experiments that attempted to optimize culture purity, 
T75 flasks were coated with laminin (see below).  All media, described below, and 
trypsin were warmed to 37°C in a water bath before use with cells. Astrocytes were 
grown in DMEM (Sigma, UK) supplemented with 10% fetal bovine serum (FBS, 
Hyclone) and 100ug/ml of penicillin and streptomycin (Sigma, UK).  After 24 hours, 
the cells were washed twice with 1x phosphate buffered solution (PBS, GIBCO, UK) 
and the media replaced.  After that, the media were changed every 4 days and, after 9-
12 days the cells reached confluency.  Once confluent, flasks were sealed with 
parafilm, and shaken for 15 hours at 180rpm in an incubator heated to 37°C.    After 
the 15 hours the media were removed.   See ‘Media Cells’, below (Section 3.1.2.) 
 
We employed several different grown conditions for the astrocytes to 
determine if these had an effect on astrocyte culture purity.  We tried growing 
astrocytes in flasks with or without laminin (20µg/mL) and/or with or without the 
addition of 10µM cytosine arabinoside (AraC, Sigma, UK), 8 days after starting the 
culture. Flasks were coated with laminin, by diluting a concentrated aliquot in 5mL of 
1x PBS, which was then added to the flask, for approximately one hour.  The laminin 
solution was then removed and cells were added immediately afterwards.   The AraC 
was replaced after 2 days and then the culture was fixed after another 2 days.  AraC as 
is a mitotic inhibitor, which should have prevented the growth of microglia on top of 
the confluent astrocyte layer (see (Saura 2007). After these experiments were  
performed (see results, section 4.1) all future experiments used flasks coated with 
laminin but without AraC. 
 
 
 
 
 
 
  
 
 
Dilute laminin to 20ug/mL in 5mL of PBS and add to T75 flasks  
 
 
 
 
 
Sacrifice P0 mouse pups  
 
 
 
 
 
 
Dissect corticies and remove meninges and hippocampus 
 
 
 
 
 
 
Use scalpel to dice 6-10 so dissected corticies into <1mm
3 cubes 
 
Suspend cubes in 5mL DMEM per 2 corticies and vortex for 90 seconds 
 
 
 
 
 
Sieve contents with cell strainer 
 
 
 
 
 
 
 
Remove laminin solution from flasks and add 10mL of warmed astrocyte media 
 
 
 
 
 
 
Add 5mL of cell solution to each flask and place flask in incubator 
 
 
 
 
 
 
24hrs later > wash cells twice with PBS and replace media 
 
Change media every 4 days after that. Cells will reach confluency at 9-12 days 
 
 
 
 
 
 
Shake confluent flasks at 180rpm for 15 hours 
 
 
 
 
 
 
Meanwhile Coat coverslips in a 24 well plates and 6 well plates with 10ug/mL poly-L-lysine  
 
 
 
 
 
 
Next day at 14 hours wash coverslips and plates twice with PBS and leave to dry for 1hr 
 
 
 
 
 
 
Seed cells on plates/coverslips   
 
 
 
 
 
 
 
Coverslips 3-4 days to grow to confluency  6- well plates, 1-2 days  35mm dishes  1-2 days 
 
 
 
Fig 3.  Astrocyte cell culture flow chart.  
 
 
       
 
 
 
 
 
 
 
 
Fix for Immunocytochemistry 
 
 
 
Make Cell lysates for western blotting 
 
 
Use in calcium experiments 
  
The confluent cell layer was trypsinized, using 0.025% trypsin-EDTASigma, 
UK), gently separated into a single cell suspension with a 10mL pipette and seeded at 
40,000 cells/well on a 24 well plate.  Each well on the 24-well plate contained a poly-
L-lysine-coated cover slip.  Cells grown on coverslips were later used for 
immunocytochemistry (See Section 3.2). and/or at 150,000 cells/well on poly-L-
lysine-coated 35mm
2 6 well plates or 35mm
2 petri dishes to produce cell lysates for 
western blotting (section 3.3) or for calcium experiments (section 3.4), respectively. 
To coat the coverslips poly-Lysine was diluted 10µg/mL to 10µg/mL in distilled H2O 
and left overnight, they were then washed three times with PBS and left to dry for one 
hour before use. Coverslips for immunocytochemistry were fixed in 4% 
paraformaldahyde for 10 minutes, after 3-4 days of growth on the coverslips.  Cells 
grown on coverslips took at least two days to resume normal morphology and cover 
the coverslip.  6 well plates took 1-3 days to settle and become confluent within each 
well. 
 
3.1.2. Media Cells 
After shaking, the media from the astrocyte flasks was either disposed of or 
spun in a centrifuge at 1500rpm for 10minutes, resuspended and plated onto two 
coverslips.  These cells that I designated as “media cells” were grown in 50% 
astrocyte-conditioned media for 3-4 days before fixation. 
 
3.1.3. Whole Brain Cell Culture 
Intact brains, including meninges of 2 P0 mice were removed, cut into cubes 
of less than 1mm
3, vortexed and cultured as above and then stained for various 
markers. Whole brain cultures were not shaken before seeding on coverslips, in the 
same manner as the astrocyte cultures. 
 
3.1.4. pH Experiment 
Media was adjusted to pH 5, 6 and 7.2 using concentrated HCl, NaOH and a 
pH meter.  Normal media, used as a control, has a pH of 7.72.  Astrocytes, grown on 
poly-L-lysine coverslips, as described in section 3.1.1, were incubated for 2hrs or 
overnight with the medias at different pHs, then fixed with 4% paraformaldahyde and   
analyzed using immunocytochemistry staining against GFAP as decribed in section 
3.2. 
3.1.5. Cell Seeding 
To seed the astrocytes at appropriate cell numbers, 10µl of an original cell 
suspension were diluted in 90 µl of supplemented DMEM. 10µl of this diluted cell 
suspension were then pipetted into a haemocytometer.  Cells in 5 quadrants of the 
haemocytometer were counted and from this the number of cells was calculated   
 (count: 5 x 10, to account for dilution, and x 10
4 to account for volume, i.e, to find 
the number of cells per ml).  Subsequently, a volume of cell suspension was 
calculated, to obtain the required number of cells per well. Astrocytes usually 
attached and regained a typical morphology over a time of about 4 days, after which 
the cells also grew to confluency. 
 
3.1.6. Cell Counting and analysis 
The Zeiss axioplan epifluorescent microscope was used for cell counting and 
analysis.   Astrocyte coverslips, stained for GFAP, were analyzed, by selecting 6 
random spots per coverslip, and counting for the proportion of GFAP immunopositive 
cells vs. total DAPI-stained nuclei.  
            
3.1.7. Infection of Astrocytes using an Adenovirus carrying httEx1-Q25/Q97  
A Wyttenbach and S.Hands ((Hands, Mason et al. 2010 and unpublished 
results) have created and amplified several adenoviruses that were provided for my 
study as hugly purified aliquots.  The AdEasy system was used for the construction of 
httEx1-Q25/Q97-mRFP (monomeric red fluorescent protein) recombinant 
adenoviruses. These viruses were made by assembling the httEx1-Q25/Q97-mRFP 
cassettes into the transfer vector, and subsequently transferred into the adenovirus 
genome, by homologous recombination.  
Cells were trypsinised as mentioned previously and appropriate numbers of 
cells in suspension was calculated by using the haemocytometer.  
 
  
Table 2. The number of cells and volume for infection used based on plate size. 
Virus Infection 
(In suspension) 
No. cells per well 
 
Volume for 
infection 
6 well plate 
24 well plate 
96 well plate 
50,000 
10,000 
10,000 
1500µl 
300µl 
200µl 
 
For my experiments using astrocytes, I added a multiplicity of infection (MOI) 
of 10 (calculated by Umar Sajjad in the Wyttenbach lab.) of Q25 and Q97-mRFP 
virus to 6 well and 24 well plates of astrocytes.  Virus was added in 1mL of media for 
the six well plates and 0.5ml for the 25 well plates.   Plates were mixed by slow 
rotation every 12 minutes five times and incubated at 37°C in between. The media 
was then changed 24 hours after incubation. 
   
3.2. Immunocytochemistry 
Astrocytes were washed with 1xPBS and then fixed in 4% para-formaldehyde 
for 10 minutes at room temperature and then washed again with 1xPBS prior to 
immunocytochemistry.  Nonspecific binding was blocked by using 400 µl of 0.2% 
triton X100, 1% BSA and 1xPBS on each coverslip for 30 minutes. Subsequently, 
cells were incubated with primary antibodies for 1 hour at room temperature or 
overnight at -4°C in the case of CNPase, diluted in 500ul of blocking agent.  The 
coverslips were thoroughly washed in 1xPBS by dipping them 5-6 times each in 6 
separate 50ml beakers.  Cells were incubated with secondary antibody (1:500) for 1 
hour at room temperature, in the dark, and then washed again with 1xPBS as before. 
Cells were DAPI stained with a 1:1000 dilution of Hoechst for 5 minutes. Cells were 
then washed again with dH2O and allowed to dry.  Finally, slides were labelled and 
the coverslips were mounted on them with Vectashield with DAPI (Vector Labs) to 
settle down for a couple of hours at room temperature and then stored at 4 ºC in the 
dark until analysis.  GFAP-stained coverslips were counted by the method described 
below.  Images were taken of the remaining coverslips, using a Zeiss LSM 510Meta 
Axioscope 2 confocal microscope.  
3.2.1. Antibodies 
The antibodies used are shown  in Table 2 for experiments, at the listed 
dilutions.  All secondary antibodies were used at 1:500 dilution for 
immunocytochemistry and 1:10000 for western blotting.  
Table 3. Antibody list 
Primary 
Antibody 
Working 
Dilution 
Company  Immunocytochemistry 
Secondary Antibody, 
Sigma, UK.  
Western blotting 
Secondary 
antibody 
Guinea pig 
anti-Glutamate 
transporter 
(GLT-1) 
polyclonal 
1:1000 
WB 
Chemicon 
(AB1783) 
  Goat-anti-GP IgG-
HRP  
Jackson 
ImmunoResearch 
(106-035-003) 
Rabbit anti-
mouse GLT-1 
1:1000 
WB 
Donated by 
J.Rothstein) 
  Goat-anti-Rabbit 
IgG-HRP 
Jackson 
ImmunoResearch 
(111-035-045) 
Mouse anti-
GFAP mAB  
1:1000 
Immuno 
+WB 
Cell 
Signalling 
technology 
(3670) 
Rabbit anti- mouse IgG 
Alexa Fluor-488 (A-
11059) 
Goat anti-mouse 
IgG - IR-dye800 
 Rockland  
(610-132-121) 
Rat anti-
mouse CD68 
(FA-11) mAB 
1:250  Serotec 
(MCA1957) 
Goat anti-rat IgG Alexa 
Fluor-555 (A-21434) 
 
             - 
Mouse  anti 
CNPase mAB 
(11-5B) 
1:200  Abcam 
(Ab6319) 
Goat anti-mouse IgG Alexa 
Fluor-555 (A21422) 
 
             - 
Rabbit anti-
connexin 43 
mAB 
1:1200 for 
immuno 
1:2000 for 
WB 
Sigma 
(C6219) 
Goat anti-rabbit IgG Alexa 
Fluor-555 (A-21428) 
Goat anti-rabbit 
IgG Alexa Fluor- 
680 
Molecular Probes 
(A21076) 
Rabbit anti-rat 
Aquaporin 4 
polyclonal 
1:250  Alpha 
Diagnostic, 
Autogen 
Bioclear 
(AQP4-1A) 
Goat anti-rabbit IgG Alexa 
Fluor 555 (A21428) 
 
 
             - 
Mouse anti-
αβC 
polyclonalAB 
1:500 
 
Stressgen 
(SPA-222) 
“               - 
Mouse anti-
HSP27 mAB 
1500  Stressgen 
(SPA-800)  
“                - 
  
3.3. Western Blotting  
3.3.1. Protein Extraction 
Protein was extracted from the astrocytes using the following method: Three 
9.6cm
2 wells of a 6 well plate were trypsinized for 4 minutes and then combined 
in10mL of ice cold media and transferred to a 15mL tube. Cells were then centrifuged 
at 4 ºC for 4 minutes, at 2000rpm. Supernatant was removed by pump aspiration using 
a pasteur pipette and then 10ml of ice cold 1xPBS was added without disturbing the 
pellet. Cells were centrifuged again at 4ºC for 2 minutes, at 3000 rpm. The 
supernatant was removed again and the pellet was resuspended in 40µl of ice-cold 
lysis buffer.  The lysis buffer for GLT-1 western blots consisted of 65.2mM Tris 
HCL, 2%SDS and 10% saccharose.  The lysate was then incubated on ice for 20 
minutes and stored at -20 ºC until required. 
3.3.2.  BioRad protein assay  
Diluted cell lysate (1:4), were assayed to determined protein concentration, 
using the BioRad Dc protein assay kit (BioRad, UK). Quantification was done using a 
bovine serum albumin (BSA) standard curve (0.031mg/ml - 2mg/ml) in a 96 well 
plate following the protocol provided in the BioRad Dc protein assay kit. Samples 
absorbance was read at 680nm using a BMG-Labtech (Fluostar 513-2055) plate 
reader.  Protein concentration measurements were used to ensure equal loading of  
samples by using this assay prior to running a SDS-polyacrylamide Gel 
electrophoresis (SDS-PAGE). 
3.3.  SDS-Polyacrylamide Gel electrophoresis (SDS-PAGE) 
The Atto protein gel system was used for SDS-PAGE gels. A 12% resolving 
gel and a 5% stacking gel were used. The gel reagents are in the table below: 
 
 
 
 
 
 
12% resolving gel  5% stacking gel 
3ml of 30% acrylamide 
2ml Tris, pH 8.8 
80µl 10% SDS 
2.92ml water 
100µl of 10% APS 
10µl TEMED 
0.83ml acrylamide  
0.63 ml Tris pH6.8 
3.4ml water  
50 ml of 10%SDS 
50µl of 10% APS 
5µl of TEMED 
  
TEMED was used to polymerise gels and it was added just before pouring 
them. Firstly, resolving gels were poured and overlaid with isopropanol until the gels 
polymerised.  The isoproponol was then poured away and then dried off completely 
using Watman paper. Stacking gels were then poured onto the resolving gels. Gel 
combs were inserted immediately after pouring the stacking gels. After the stacking 
gel polymerized, the gel’s seals were taken off and washed carefully with distilled 
water. The poured gel and glass plates were placed into a gel tank, containing 1X 
running (Laemmli) buffer (.025MTris, .192 glycine 1% w/v SDS), and gel combs 
were removed. Loading wells were washed with a pipette. Samples were then diluted 
to 1µg/µl in loading dye which was diluted in lysis buffer with the following 
composition: 50mM Tris-Cl (pH 6.8), 2% SDS, 0.1% bromphenol blue and 10% 
glycerol.  Samples were then heated at 95ºC for 4 minutes and spun at 13000rpm for 2 
minutes at room temperature prior to loading. 20µl of each sample and 10µl of 
prestained protein marker (Cell Signalling) were loaded into the wells of the gel. Gels 
were run at 30mA until the dye passed through the stacking gel. The current was 
subsequently increased to 60 mA and gels were allowed to run until the dye exited the 
resolving gels. 
3.3.4.  Coomassie Staining 
Gels were soaked for 1 hour in Coomassie stain (Sigma) mixed with 50% 
methanol and 10% acetic acid to visualise protein. Subsequently, gels were destained 
overnight, in a destain buffer consisting of 10% methanol and 10% acetic acid in 
distilled water. Gels were then scanned 700 and 800nm on the Li-COR scanner 
(Biosciences) and quantified by using Odyssey v1.2 software. 
3.3.5.  Semi-dry protein transfer 
Whatmann's blotting paper and nitrocellulose membranes were soaked in 
transfer buffer (35mM glycine, 48mM Tris base, 0.37% SDS, 20% methanol). Five 
pieces of whatmann paper were placed on the semi-dry protein transfer apparatus 
followed by the nitrocellulose membrane and then the gel.  Five layers of whatmann 
paper were then placed overtop of the gel. The surface area of the gel was measured 
and multiplied by 1.54 to find out the required current in milli Amperes (mA) for 
protein transfer. The current was then applied for 90 minutes. Protein transfer was  
confirmed by staining the membranes in 0.1 % Ponceau Red for 10 minutes and then 
washed with distilled water. Nitrocellulose membranes were scanned, by using a 
Cannon laboratory scanner. 
3.3.6.  Membrane immunoblotting 
Nitrocellulose membranes were blocked with 1 x TBS- 0.1% Tween (TBS-T) 
and 4% milk for 30 minutes at room temperature. Membranes were then washed 
twice with TBS-T for five minutes and then incubated overnight, with primary 
antibody at 4ºC with shaking. Primary antibody was diluted in TBS-T and 4% BSA. 
  Membranes were washed thrice in TBS-T for ten minutes and then incubated 
with a suitable fluorescent or horseradish peroxidase (HRP) secondary antibody for 
one hour at room temperature. The membranes were washed thrice more in TBS-T for 
ten minutes at room temperature with constant shaking. Fluorescent secondary 
antibody labelled membranes were scanned with a Li-COR scanner at 700 or 800nm 
(depending on antibody), whereas HRP labelled membranes were analysed by using 
the Enhanced Chemiluminescence (ECL) method, as described in the manufacturers 
handbook (Biorad).  
 
3.4.  Measurement of Intracellular Calcium  
  Astrocytes grown to confluency, as described above (Section 3.1.1.), were 
trypsinized and replated onto 35mm
2 plastic dishes and left to settle and reach 
confluency, once more, for four days. These cells were then incubated with 10µM 
Fluorescein-3 acetoxymethyl (Fluo-3AM) (Invitrogen) for one hour at 37°C.  Cells 
were then washed in 1xPBS three times and fresh pre-warmed astrocyte media was 
added.  The cells were then allowed to sit for thirty minutes in the incubator, giving 
time for the intracellular esterases to remove the acetoxymethyl, so that the fluo-3 
could fluoresce.  
 
  After 1 minute of measurement, to obtain a reading of background florescence, 
the media was then changed to different concentrations of ionomycin (1µM, 2.5µM, 
5µM 10µM) in DMEM using a peristaltic pump.  This pump adds one fluid and 
removes another simultaneously.  In these inonomycin experiments the pump added  
7mL of ionomycin solution over the course of the experiment and removed 5mL of 
solution, maintaining a constant volume of 2ml in the 35mm dish.  Changes in 
florescence were then continuously measured at one second intervals for 250-400 
seconds.  In some experiments (data not shown) 1% Triton and 5mM EGTA were 
added, after the peak florescent intensity was reached, in order to see if that was a 
suitable means of obtaining a minimum value for background intensity in the absence 
of calcium signal (Fmin). In one experiment, 10µM ionomycin diluted in Hank’s 
solution (10 mM  CaCl2, 150 mM KCl, 1 mM MgCl2, and 10 mM Na- HEPES  
pH7.4) were added to a 35mm dish.  This allowed me to see more easily, when the 
solution changed from DMEM to our ionomycin solution, as the former is pink and 
the latter is clear.  The use of this solution, perhaps due to it’s high calcium 
concentration gave us a result whereas inomycin in DMEM did not.   
 
4. Results 
4.1. Astrocyte Culture Purity 
The first goal was to reproduce the 95% GFAP positive astrocyte cultures, that 
are the standard used in most astrocyte literature (reviewed in Saura, 2007). The 
methods, described above, closely replicate those used elsewhere. I grew astrocytes 
first on plastic, on laminin and with or without AraC.  I found that the best condition 
for astrocyte growth was on laminin without AraC where I was able to achieve, at 
most, 84% GFAP positive cells as determined by counting GFAP immunopositive 
cells vs DAPI stained nuclei (fig.5 and fig. 6). I also tried growing cells on laminin 
and changing media every 3 days instead of every 4 but neither of these had any 
significant effect on the proportion of GFAP positive cells.  One possibility is that 
some of the cells I counted as GFAP negative were astrocytes that express low levels 
of, or no, GFAP.  Populations of entirely GFAP negative astrocytes do exist (e.g. 
(Walz and Lang 1998).  Altering the GFAP antibody concentration did not, however, 
produce higher GFAP+ve cell counts due to excessive background staining (fig. 7.).  
 
In order to find out if there were astrocytes that expressed low or no detectable 
levels of GFAP I employed a method known to upregulate GFAP expression in 
astrocytes (Lee, Du et al. 2000).  The immunocytochemistry of the experiment does  
suggest that, as previously reported, incubation for two hours in low pH conditions 
(fig. 7), increased GFAP expression and the % of GFAP positive cells vs DAPI 
positive nuclei. Overnight growth at pH 5.56 killed the cells.  At pH 7.2, it had no 
effect on the % of GFAP+ve cells.  
 
I also made an attempt to see if some portion of the 15-20% of cells that were not 
counted as GFAP+ve were other cell types. My data below indicates that there are no 
detectable microglia or oligodentrocytes within the cultures and that the remaining 
15-20% of cells are mostly astrocytes or astrocyte precursors, meningeal fibroblasts 
or ependymal cells.  Previous literature reports the presence of oligodendrocytes, 
microglia, neurons, endothelial cells, meningeal fibroblasts and endothelial cells in 
small proportions in astrocyte cultures (Saura 2007).       
 
 
Fig 4. Cells grown on plastic, replated on Poly-L-Lysine for four days, fixed and 
stained with GFAP antibody, an astrocyte marker.  40X. 
 
  
 
Fig 5. Astro cultures grown on different substrates conditions.  % cells that are GFAP 
positive.   Control (n=3), AraC (n=2), Laminin (n=9) Lam+AraC (n=3). GFAP 
antibody used at 1:1000 dilution. There was a significant difference between the % of 
GFAP+ cells under the control conditions and when using AraC.  However there is no 
significant difference in the % of GFAP+ cells between those grown on Lam and 
those grown with Lam+AraC. 
 
 
Fig 6. Test to see if primary GFAP antibody concentration affected the count of 
GFAP positive cells (n=2 for each antibody dilution).  There is a non-significant trend 
towards 1:1000 dilution producing slightly higher counts due to less background 
staining. 
 
 
  
 
Fig 7. Cells grown on laminin and then subcultured on poly-L-lysine were exposed 
media that had been adjusted to several different pHs. Normal media had a pH of 7.7.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
   
          
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
Culture  Microglial 
Number 
9/08 Astro-Laminin  0 
11/08 Astro-Laminin  0 
12/09 Astro Laminin+ AraC  0 
03/09 Laminin FBS sigma   5 
12/10 Whole brain   Many 
16/11 6-well plate  6 
16/11 Astro- Laminin  0 
 
      A. 
 
      B. 
 
      C. 
 
      D. 
 
      E. 
 
      F. 
 
      G. 
 
 
 
Fig 8. A.) Whole brain cell culture, putative microglia 40x  B.) Whole brain cell culture, FA-
11 staining 40x. C.)  Astrocyte culture grown on laminin, shown before shaking. Putative 
microglia marked with arrows, 20x.  D.)  Whole brain culture as a control, Goat anti-rat 555 
secondary antibody only, 20x.  E.) Astrocyte culture grown on  laminin (16/11/08) stained for 
FA-11.  No specific staining,  20x.  F) Microglia numbers depending on culture.  
 
  
4.2. Microglia 
A small amount of microglial contamination in the astrocyte cultures could 
have a disproportionate effect on any future experiments.  Even small quantities of  
microglial cytokines can alter astrocyte phenotype and responses to other stimuli 
(Reviewed in (Saura 2007).  
 
In order to obtain a positive control for microglial cells, whole brain cultures were 
established, which indeed had a considerable number of phase bright cells on top of 
the monolayer, that I posited might be microglia (fig.8A) stained positive for FA-11, a 
marker of tissue macrophages (fig 8B).  Astrocyte cultures occasionally showed some 
phase bright cells prior to shaking (fig. 8C).  In cultures grown on laminin, these 
phase-bright cells were not present after shaking. I stained coverslips from all of the 
different culture-conditions using the antibody FA-11, to examine microglial 
contamination and found that cells grown on laminin had no detectable microglia (fig. 
8F). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.3. Oligodendrocytes 
One possible culture contaminant is oligodendrocytes.  These cells do release growth 
factors which could interfere with future experiments (Byravan, Foster et al. 1994).  I took the 
media from shaken astrocyte cultures and plated these onto coverslips.  After 3-4 days of culture 
this produced cells with extensive processes (fig. 9A, B) that covered 20-30% of the coverslip. 
These cells proved to be immunopositive for CNPase, an oligodendrocyte marker (fig. 9C, D).  
An astrocyte culture grown on laminin did not show any positive anti-CNPase staining (fig. 9F) 
and none of the astrocyte cultures, after shaking, were observed to have any cells with an 
oligodendrocytic morphology. 
 
 
 
 
. 
   
 
 
      A. 
 
       B. 
 
       C. 
 
       D. 
 
Fig 9.  Astrocyte cultures were shaken overnight at 180RPM to remove culture contaminants.  
To identify these contaminants we centrifuged the media (1500RPM, 10min) taken from the 
flasks after shaking and plated them on poly-L lysine coated glass coverslips.  A.) Media 
cells, putatively Oligodendrocytes, 63x. B.)  Media cells, putatively Oligodendrocyte, 63x. C 
and D.) Examples of media cells stained with an anti-CNPase antibody, an oligodendrocyte 
marker,. 40x. 
 
 
  
 
 
           
           
           
           
 
 
 
 
4.4. Astrocytes, Ependymal Cells and Meningeal Cells 
Connexin 43 (Cx43) is a major gap junction component in the CNS.  It is 
highly expressed in the gap junctions, involved in the syncytial network of astrocytes, 
but is also expressed by microglia (Eugenin, Eckardt et al. 2001), ependymal cells 
(Ochalski, Frankenstein et al. 1997) and meningeal cells (Nagy, Patel et al. 1999).  
Microglial expression of Cx43 is generally low.  Less than 5% of microglia, in the 
adult mammalian CNS, express Cx43 and only very low levels are found in cultured 
microglia. Meningeal cells express high levels of Cx43 and are closely coupled. I 
stained a culture grown on laminin with anti-connexin 43 antibody and showed a 
ubiquitous expression of Cx43.  Every DAPI- positive nuclei in the culture was 
surrounded by a ring of Cx43 positive staining (fig. 10A,B,C).  Previous staining 
strongly indicated that there were very few or no microglia in the cultures grown on 
laminin and shaken. Fibroblasts do not stain positive for Cx43.  Hence, it is likely that 
the remaining 15-20% of cells, that were not GFAP positive in the astrocyte cultures, 
were astrocytes, or their progenitors that expressed no or low levels of GFAP (Walz 
and Lang 1998), ependymal cells or meningeal cells. A meaningful quantity of 
meningeal cells is unlikely given that we removed the meninges as part of our 
dissection.  There are not many ependymal cells in the mouse brain.  Nonetheless, It 
would make sense to try nestin, a marker of stem and progenitor cells as well as an 
ependymal cell marker. 
 
       E. 
 
       F. 
 
Fig 9. E.) Media cells.  Goat anti-mouse 488 secondary antibody only. F.) Astrocytes grown 
on laminin stained with anti-CNPase antibody, 40x.  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
   
     
 
   
      A. 
 
      B. 
 
      C. 
 
      D. 
 
Fig 10.  Astrocyte cultures grown on laminin stained with Anti-Connexin 43 (Cx43). Cx43 is 
a gap junction protein expressed in the brain only in astrocytes, microglia, ependymal cells 
and meningeal cells. In our cultures a ring of Cx43 surrounded every DAPI-positive nuclei.  
A.) Cx43, 20X. B.) Cx43, 40X.  C.) Cx43, 63X.  D.) Goat anti-rabbit 555 secondary antibody 
only,  20x. 
 
 
  
   
4.5. Aquaporin 4 
  To examine some of the variability amongst astrocytes I stained my cultures 
with Aquaporin 4 (AQ4).  AQ4 is highly expressed in vivo in the endfeet of astrocytes 
next to blood vessels and is involved in mediating the movement of water across the 
blood-brain barrier.  In culture, 15% of the astrocytes expressed AQ4 (fig. 11A). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A.  B. 
Fig 11. In vivo Aquaporin4 (AQ4) is expressed in the endfeet of astrocytes associated with 
blood vessels.  In our culture 15% of the cells expressed AQ4 and this was not restricted to 
endfeet. A.) Astrocyte Culture grown on laminin. Stained with anti-Aquaporin 4 antibody, 
40X. B.) Astrocyte Culture grown on laminin. Goat anti-rabbit 555 secondary antibody only, 
20x.  
4.6.  Calcium Measurement in Astrocytes 
Next, the astrocyte cell culture system characterised above was used to set up 
a means of measuring changes in intracellular calcium concentration.  One of the 
most commonly used tools for this is Fluorescein-3 acetoxymethyl (fluo-3AM) . 
 
  Fluorescein-3 (fluo-3) 
is a cell impermeable indicator 
that, when bound to a calcium 
ion, emits green fluorescence, 
(525nm) in the presence of 
visible light (-425nm).   
The intensity of emitted 
fluorescence depends on the 
free calcium concentration (fig. 
12).  The acetoxymethyl (AM) 
ester derivative of Fluo-3 is 
lipid-soluble, hence able to 
pass through cell membranes, 
but non-fluorescent.  Intra-cellular esterases break Fluo-3 AM ester down into AM 
and active Fluo-3.    
 
Measurements, using Fluo-3, are quantified in terms of relative florescent 
intensity.  Fluo-3 intensity values have to then be converted into estimates of calcium 
concentration, as described previously (Minta, Kao et al. 1989; Kao 1994).  The free 
Ca
2 concentration, for a given florescent intensity (F), is calculated by: 
 
                        
The Kd, for Fluo3 at 37◦C, in astrocytes, is 385nM (Kao, Harootunian et al. 
1989).  Fmax is the maximum intensity possible under the same experimental 
conditions and using the same cells used to determine F. Fmin is the background 
fluorescence and can be measured by removing all other fluorescence by quenching 
or ablating the fluor-3AM. I experimentally determined Fmin and Fmax values by 
 
 
 
[Ca
2+]  =  (F – Fmin) 
 
 
 
(Fmax – F) 
 
________
_ 
 
 
Kd ● 
 
Fig 12.:  Ca
2+-dependent  emission spectra of 
fluo-3. Invitrogen, 2010.   
using Triton, ionomycin and EGTA. Triton-X 100 is a non-ionic detergent most 
commonly used for solubilising membrane proteins, or for permeabilizing cell 
membranes, in immunocytochemisty.  
 
The standard way of calibrating a calcium-sensitive dye is to employ an ion-
specific ionophore.  Ionophores are lipid soluble molecules able to transport ions 
across the lipid bilayer.  Ionomycin and BrA23187 are the most commonly used 
calcium ionophores for this type of calibration.  Of these, ionomycin is a more 
efficient calcium transporter.  Ionomycin loses two acidic hydrogen ions and can form 
a complex with calcium at a 1:1 ratio.  Br-A23187 can only lose a single acidic 
hydrogen and, hence, it requires two molecules of Br-A23187 to bind and carry a 
single ion of Ca2+.  Furthermore, ionomycin has been shown to be twice as selective 
for Ca2+ over Mg2+, whereas Br-A23187 does not have a preference for one cation 
over another (Liu and Hermann, 1978).  BrA23187 is more efficient under acidic 
conditions (pH<6.0), but my experiments were conducted at physiological pHs. 
 
  Ionomycin is fairly inefficient at mediating Ca
2+ transport at low Ca
2+ 
concentrations (Kao 1994).  Hence, when I conducted a calibration experiment in 
DMEM alone, at varying concentrations of ionomycin, there was very little intensity 
change (fig 13A-D).  However, in a solution containing 10mM CaCl2, 150 mM KCl, 
1 mM MgCl2, and 10 mM Na-HEPES pH7.4 (as used in (Nadal, Fuentes et al. 1996)) 
there was a substantial increase in intensity. Also, the increase in intensity was 
maintained for much longer (fig.13E, F). This is the standard means of measuring 
Fmax and should be suitable for any future experiments.  Fmin can be measured by 
treating the cells with 1% Triton and 5mM EGTA, which caused a reduction of 
florescence to background levels probably due to a combination of the dye leaking out 
and the calcium being quenched by EGTA.    
  
  With ionomycin and 1% Triton +EGTA, I have now established a means of 
measuring Fmax and Fmin. This system could be readily used to examine astrocyte 
calcium wave dynamics as, given an experimentally determined Fluo-3 florescent 
intensity from stimulated cells, it is possible to estimate calcium concentration.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  A. 
Fig 8d. 
 
   
[ionomycin]  Baseline 
Intensity 
Time  Peak 
Intensity 
Time  Fold 
increase 
1 uM  30.5  104  35  253  1.15X 
2.5 uM  29.4  133  35  198  1.19X 
5 uM  61.5  112  64.1  160  1.04X 
10uM  97.4  94.4  97.4  94.4  1X 
10uM in 
10mM CaCl2 
10.4  102  44.2  315  4.25X 
  
Fig 13. Astrocytes treated with increasing levels of ionomycin in DMEM.  Ionomycin added 
at IE and stopped at IS. EGTA + 1% Triton added at E A.) 1uM Ionomycin, B.) 2.5uM 
Ionomycin, C.) 5uM Ionomycin, D.) 10uM Ionomycin.  E.)  Astrocytes treated with 10uM 
ionomycin in 10mM CaCl2, 150 mM KCl, 1 mM MgCl2, and 10 mM Na-HEPES pH7.4. 
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  D. 
     E. 
       F.  
4.7. Glutamate transporter changes and Huntingtin 
GLT-1 expression is known to decrease, in the presence of misfolded htt, in 
transgenic mice, expressing htt in all cells or just in astrocytes, astrocytes cultured 
from mouse models of HD and from mouse astrocytes infected with adenovirus. 
Therefore, I attempted to repeat these findings, in both cultured astrocytes and using 
lysates from wild type mice and R6/2 transgenic mice. 
 
To label GLT-1 I used an antibody provided by J.Rothstein (Johns Hopkins 
University, Department of Neurology).  I first used whole brain lysates, from three 
wild-type mice (Wt), two R6/2 mice, normal brain homogenate (NBH) and Me7 prion 
mouse (fig. 14).  Wt and R6/2 brain samples were kindly provided by A.J. Morton 
(University of Cambridge, Department of Pharmacology).  Given that the GFAP 
staining and Ponsceau show even loading for the first five lanes this blot shows a 
clear decrease in GLT-1 staining between R6/2 and control.  The NBH and Me7 
samples were provided by A. Deji (Southampton University, Department of 
Neuroscience).  The GLT-1 blot shows bands of approximately even intensity 
between NBH and Me7 but since NBH is underloaded according to the GFAP loading 
control and the Ponsceau stain this blot also implies a loss of GLT-1 in prion disease. 
 
In order to examine the effects of expanded polyglutamine protein on 
astrocytes, I employed two htt-Ex1 recombinant adenoviruses, one with a vector, 
encoding a polyglutamine sequence 25 amino acids long, and another, 97 amino acids 
in length.  These viral vectors also contain a sequence encoding mRFP linked to the 
C-terminus of httEx1. These viruses were constructed by S. Hands and purified by A 
Wyttenbach in the laboratory.  Subsequently, both adenovirus preparations were 
titrated, to obtain an estimation of viral particle concentration (data not shown).  After 
infecting astrocytes with a multiplicity of infection of 10 of each virus (fig. 15A-C), 
the number of mRFP positive cells (~1-10% at day 1, 30-50% at day 3 and 80-90% at 
day 6) and, in the case of the Q97 cells, the number of aggregates (~.2-1% at day 1, 
20-30% at day3, 33-50% at day 6) , increased over time. Western blotting using S830, 
an antibody against the N terminus of htt, showed increasing amounts of Q25 and 
Q97 proteins from D1-3 (fig16D-G).  On day 6, Q25 protein levels increased,  
according to the western blots, however Q97 protein levels were less than at day 3.  
The likely explanation is that the SDS-insoluble Q97 aggregates remained in the 
stacking gel.     
 
Having established western blotting conditions for animal lysates, I tried to 
recapitulate these results in cultured astrocytes.  I started by treating confluent 
astrocytes with 1-6 days of dybutryl cAMP and forskolin, as based on the work of 
(Schlag, Vondrasek et al. 1998); Figiel, Maucher et al. 2003), it is known that these 
two increase cellular expression of GLT-1   My western blotting data seemed to 
support this, as it showed a slight trend towards increasing GLT-1 expression over 
time  (fig. 16).  In my next experiments, in a variety of conditions (fig. 17) I produced 
positive staining for GLT-1, but there was no discernable trend towards a decrease in 
GLT1, four days after infecting the astrocytes with either Q25 or Q97 mRFP virus. 
There was some indication of a decrease in GLT-1, in the presence of Q97 virus, at 
day 6 after infection, that was not seen with Q25 virus (Fig18A8 vs A9). I might have 
been able to produce more clear and consistent results with further experiments. 
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Fig 14.  Western blot of whole brain from wild type and R6/2 mice as well as 
NBH and ME7. A.) Western blot using Rabbit anti-mouse GLT-1 (1:1000 
donated by J. Rothstein). This antibody stains for GLT-1 at 70Kda according 
to (Rothstein, Martin et al. 1994)  B.) Reprobe of membrane with mouse anti-
GFAP mAB (1:1000, Cell Signalling Technologies). C.) Ponceau stain to show 
equal loading. 
A. 
B. 
C.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 15.  Astrocytes on poly-L-lysine glass coverslips exposed to mRFP adenovirus or 
control for three days prior to fixation with 4% paraformaldahyde. A.) Control cells.  B.) 
Q25-mRFP infected cells.  C.) Q97 infected cells.  Note the presence of abnormally 
shaped or condensed nuclei in the cells associated with Q97 as compared to either control 
or mRFP infected cells. 
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Fig 16.  Western blot of cultured astrocytes after 1-6 days of Q25 or Q97 mRFP 
adenovirus infection vs. control. A.) Sheep anti-human antibody (Gill Bates).  B.) 
Ponceau stain for blot A.).  C.) Second Western blot of same lysates as a).  D.) Reprobe of 
membrane with mouse anti-GFAP mAB (1:1000, Cell Signalling technologies). 
 
 
    
 
 
 
 
 
 
                        -62kda 
D. 
E. 
F. 
G. 
 
 
 
 
 
 
 
 
                                                                                               asdfsdafadsf 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
asdfsadfasdfasdfadsf 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    1        2         3        4        5      6          7                                           
 
 
                                                  
 
          
 
 
 
 
 
 
                                                                                                                  -83kda 
 
 
             
      
 
 
 
             
 
 
 
 
 
 
 
 
                       
 
 
                              
 
 
 
 
 
                                         -62kda 
Fig 17. Western blot of astrocytes treated with db-cAMP or Forskolin. Shows 
positive GLT-1 staining from cultured astroctyes.  1) Control, 2) 1 db-CAMP-D1 
3) db-cAMP-D3 4) db_cAMP-D6 5) Forskolin-D1 6) Forskolin-D3 7) Forskolin-
D6. 8) WT mouse whole brain 9) R6/2 Mouse whole. Western blot using Rabbit 
anti-mouse GLT-1 (1:1000 donated by J. Rothstein). This antibody stains for 
GLT-1 at 70Kda according to (Rothstein, Martin et al. 1994).   
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Fig 18.  Western blot of GLT-1 from cultured astroctyes.  1) Control, 2) 1 day of 
forskolin treatment 3) 3 days of forskolin treatment 4) Q25-D4, 5) Q97 D4 6) 
Q25-D4 +1 day of forskolin treatment 7) Q97-D4 + 1 day of forskolin treatment 8) 
Q25-D6, 9) Q97-D6 10) Q25-D6 +3 days of forskolin treatment, 11) Q97-D6 +3 
days of forskolin treatment.  a) Western blot using Rabbit anti-mouse GLT-1 
(1:1000 donated by J. Rothstein). This antibody stains for GLT-1 at 70Kda 
according to (Rothstein, Martin et al. 1994). b) Reprobe of membrane with mouse 
anti-GFAP mAB (1:1000, Cell Signalling technologies). c) Ponceau stain. 
A. 
B. 
C.  
5. Discussion  
The aim of the first set of my experiments was to produce and characterize 
highly pure astrocyte cultures. I found that the best condition, under which to grow 
astrocytes, was laminin without AraC using the method described in section 3.1.1. On 
average, I counted my astrocyte cultures as being 80% pure. However it is likely that 
the majority  of the remaining 20% are astrocytes, or astrocyte progenitors, which 
express low or no GFAP.  In one experiment, I demonstrated that low pH can increase 
the percentage number of cells that express GFAP as compared to the total number of 
DAPI positive nuclei.  Its known that astrocytes exposed to acidic media for two 
hours increase their immunoreactivity for GFAP without de novo protein synthesis 
(Oh, Markelonis et al. 1995).  Lee, Du et al. (2000) showed that this low pH causes 
calcium influx into the astrocytes and an activation of the enzyme calpain-I.  Calpain-
I degrades GFAP and this paper showed an increase in small GFAP fragments in 
astrocytes exposed to low pH.  They proposed that this degradation of GFAP exposes 
new epitopes for antibody binding to GFAP which results in the observed increase in 
immunoreactivity.    
 
The remaining cells, GFAP negative cells, are not likely to be either microglia 
or oligodendrocytes, as my astrocyte cultures, grown on laminin, lack FA-11 positive 
and CNPase positive cells. Connexin 43 is a protein that, in the CNS, is only 
expressed in astrocytes, microglia, ependymal cells, neurons and meningeal cells. No 
neuron can survive the 90 seconds of rapid vortexing we use in our purification 
method and I did not see any cells with a neuronal morphology. Hence, any cells, that 
are not astrocytes, are probably fibroblasts, ependymal cells or meningeal cells.  In 
order to look at the presence of meningeal cells and fibroblasts, I performed 
immunocytochemistry with anti-fibronectin antibody and RAHLD2, an antibody 
specific for meningeal cells, (Shearer, Niclou et al. 2003), but was unable to obtain 
clear results with astrocyte, meningal or whole brain cultures. It would be good to 
find another anti-meningeal antibody, as meningeal cells are still a likely culture 
contaminant: they form separate patches, in astrocyte cultures, and alter the 
morphology of the astrocytes, with which they interact (Shearer, Niclou et al. 2003).  
Furthermore, these cells have effects on neural development neurite outgrowth  
(Niclou, Franssen et al. 2003) and can communicate directly with astrocytes via gap 
junctions (Grafstein, Liu et al. 2000).  Also, meningeal cells are capable of releasing 
proinflammatory cytokines, to which astrocytes are known to respond (Wu, Zhang et 
al. 2005).  In other studies oligodendrocytes(Wiesinger, Schuricht et al. 1991), 
ependymal cells, fibroblasts, neurons (Hildebrand, Olenik et al. 1997), endothelial 
cells (Falsig, Porzgen et al. 2006), microglia (Hansson 1984; Giulian and Baker 1986) 
and different types of precursors (Hansson 1984; Crang and Blakemore 1997) have all 
been shown to be present in mouse or rat astrocyte cultures in small proportions.  
Most astrocyte papers claim to have 95% pure astrocyte cultures in their methods (eg. 
(Brahmachari, Fung et al. 2006)) but very few recent papers publish any results 
showing the purity of their cultures.  It is likely that >80% of the cells are astrocytes 
and that my cultures conform to those used in other papers, but to confirm this, it 
would necessary to do more replicates of the aforementioned pH experiment.  It also 
would be good to use a wider range of markers in order to indentify the remaining 
cells that are not astrocytes..  Furthermore, astrocytes are heterogeneous.  The 
aquaporin 4 immunocytochemistry demonstrates some of this diversity, in that only 
15% of cells in my cultures express this marker (fig. 10).  S100β is a calcium binding 
protein expressed in mature astrocytes that surround blood vessels or   NG-2 positive 
glial progenitor cells.  Morphologically, astrocytes are categorized as either 
protoplasmic or fibrous and these types are associated with gray and white matter, 
respectively.  Metastasis-associated protein-1 (MAP1) is expressed in fibrous 
astrocytic matter but not protoplasmic and there is a novel splice variant of GLT-1 
also found only in fibrous astrocytes.  Whereas, connexin 30 (Cx30), a gap-junction 
protein unique to astrocytes, is only seen in protoplasmic gray matter astrocytes. Raff, 
Abney et al. (1983) defined two distinct populations of astrocytes derived from the 
developing optic nerve by developmental, morphological and antigenic (Ran2, 
FGFR3 and A2B2) criteria  but this distinction may purely be a cell culture 
phenomena, as it has never been seen in vivo.  Nonetheless, all these markers 
described above, could be used to further describe our cultures.  
 
My next set of experiments was to measure calcium concentration in cultured 
astrocytes, with the hope of looking at calcium wave dynamics. The addition of  
ionomycin in a 10mM calcium solution seems to produce a maximum signal and 1% 
triton and EGTA ablates that signal.   These provide the means, as given in the 
equation in the results section, to calculate calcium concentration for a given 
experimentally measured fluo-3 intensity.  The maximum possible signal, within a 
given cell system using Fluo-3, is called the Fmax which I produced using ionomycin.  
The background level of florescence in the absence of any calcium-stimulated Fluo-3 
signal is the Fmin.  In a future experiment to measure intracellular calcium 
concentration produced due to some kind of stimulation, one would record an 
intensity value first and then, after the experiment, one would use ionomycin to find 
the Fmax followed by Triton and EGTA to measure Fmin.  With this, one could then 
estimate the calcium concentration of the recorded intensity value.  Future 
experiments could produce a calcium wave, as previously published (Zhao, Zhang et 
al. 2009; Hassinger, Guthrie et al. 1996; Paemeleire and Leybaert 2000).    I tried one 
preliminary experiment, emulating Zhao, Zhang et al. (2009), who used a multiphoton 
laser to burn a hole in one astrocyte in a calcium-rich media, causing an influx of 
calcium into that cell which initiated a calcium wave.  I exposed a small focal region 
on a single cell to a confocal laser turned up to 100% at 800nm for 1min. These cells 
were suffused with 50µM propidium iodide, a membrane-impermeable nuclear stain. 
Any hole in a cell should have led to the nucleus of that cell fluorescing. I managed to 
burn a hole in the cell, but there was no PI fluorescence. I may well have destroyed 
the nucleus or overly disrupted the astrocyte.  Optimization of such experiments could 
lead to the production of a laser-stimulated calcium wave. The alternative would be to 
make electric shock-induced, or mechanically stimulated calcium waves, as described 
in Hassinger, Guthrie et al.( 1996) and Paemeleire and Leybaert (2000).  One idea 
would have been to examine calcium wave dynamics in the presence of misfolded htt, 
using our aforementioned adenovirus. Chow, Yu et al. (2009) showed that calcium 
wave dynamics are altered when cells are exposed to Aβ (Kuchibhotla, Lattarulo et 
al. 2009; Chow, Yu et al. 2009).  Others, more recently have found that some of these 
changes also occur in vivo (Kuchibhotla, Lattarulo et al. 2009).  Given the import of 
astrocyte calcium signalling in regulating cerebral blood flow and the dysregulaton or 
reduction of cerebral blood flow in a number of neurodegenerative diseases (see  
introduction section 1.5), maybe other misfolded proteins also alter astrocyte calcium 
wave dynamics.   
 
My last set of experiments was to look at the changes of GLT-1 expression 
levels, in mouse lysates and cultured astrocytes. The results, using mouse brain 
lysates from R6/2 (fig.9, fig.10), support previously published results that showed 
GLT-1 levels to be reduced in this model (Lievens, Woodman et al. 2001), in the HD 
patient brain (Hassel, Tessler et al. 2008) and in cultured astrocytes (Bradford, Shin et 
al. 2009) (See introduction section 1.3 for an overview of the related literature).   I 
then tried to look at GLT-1 expression level changes in astrocyte cultures both treated 
with forskolin or dybutryl cAMP and in the presence of polyglutamine expanded 
huntingtin.  The initial experiments with GLT-1 western blotting had low or no signal 
and hence I tried forskolin and db-cAMP.  Schlag, Vondrasek et al. (1998) observed 
that astrocytes in culture express low levels of GLT-1 despite the fact that they 
express much higher levels in vivo.  They then showed that co-culture with neurons or 
with db-cAMP, forskolin and other protein kinase A  activators led to higher levels of 
GLT-1.  In the case of db-cAMP they showed that GLT-1 immunoreactivity 
significantly increased after 3 days of treatment and reached a maximum after 14 
days.  Similarly, Zschocke, Bayatti et al. (2005) showed that 72 hours of forskolin 
treatment was sufficient to produce a significant increase in GLT-1 levels. My 
experiment (fig. 17) seems to indicate that even after one day of db-cAMP or 
forskolin there is a slight increase in GLT-1 levels and fig. 18 shows that GLT-1 
levels do, indeed, increase after 3 days of forskolin treatment.   I then tried using two 
mRFP adenoviruses, carrying either huntingtin Q25 or Q97 linked to mRFP.  Western 
blotting with the antibody S830 confirmed the presence of, and the increase in, 
huntingtin levels over six days of infection (fig. 16) Although, on day 6 in the Q97 
there appears to be less huntingtin, possibly because it forms insoluble aggregates that 
probably stay in the stacking gel.  Imaging of these cells showed an increase in mRFP 
fluorescence from day 1-6 in both Q25 and Q97 cells and in Q97 infected cells there 
were an increasing number of cells with insoluble aggregates (30-50%).  I then tried 
to look at GLT-1 loss after infection with these adenoviruses with or without 
forskolin.  These experiments produced ambiguous results but in at least one instance  
(fig. 17A) there does appear to be a decrease in GLT-1 expression after 6 days of 
infection with Q97 virus, as compared to Q25. Following these results, I carried out a 
number of western blots using similar conditions, but was unable to repeat them. The 
only differences between my protocol and published literature (e.g. (Bradford, Shin et 
al. 2009) was that they sonicated their lysates prior to heat denaturation and they 
treated their cultured astrocytes, once confluent, with db-cAMP, for 7-10days, prior to 
using them for their experiments.   Given the aforementioned papers ((Schlag, 
Vondrasek et al. 1998; Zschocke, Bayatti et al. 2005) the duration of my cAMP 
treatments should have been sufficient to be able to consistently see GLT-1 staining 
but, nonetheless, future experiments should involve attempting to sonicate the lysates 
or employing longer periods of forskolin or db-cAMP treatment.   
  
 
There are several lines of research for which this culture model would be 
suited.  One could look at alterations of calcium wave dynamics in the presence of 
mutant htt (as previously described), the bioenergetics and glucose biochemistry of 
astrocytes in the presence of mutant htt and the microarray profiles comparing neural 
stem cells, astrocytes and neurons exposed to mutant htt.   
 
It would be interesting to examine glial glycolysis and glucose transport to 
neurons in the presence of misfolded protein.  Most, possibly all, of the work 
examining how astrocytes supply neurons with energetic substrates, has been 
performed on normal animals or cell cultures and not in the context of pathology 
(Pellerin, Bouzier-Sore et al. 2007).  However, as discussed previously, there is 
considerable evidence to suggest that energetics play a role in neurodegeneration. The 
seminal paper of Magistetti and Pellerin in 1996, involved a few simple experiments 
that could readily be repeated in the context of misfolded protein. They used 2-
Deoxy-D-[1,2-
3H]glucose ([
3H]2DG)  to examine the uptake kinetics of cultured 
mouse cortical astrocytes and spectrophotometry to measure the release of lactate into 
the medium.  It would be interesting to repeat this experiment, using astrocytes 
transfected with our httEx1- expressing plasmids, or infected with the htt-Q97 or htt-
Q97/NLS adenoviruses, described above, to see if astrocyte glucose uptake or lactate  
release is significantly affected by the presence of misfolded protein. If this is so, one 
could then examine the mechanism of disruption. Future experiments might include 
examining the effect of astrocytic mitochondrial dysfunction on neuronal health. 
Given that brain glycolysis mostly occurs within astrocytes (Pellerin, Bouzier-Sore et 
al. 2007) and NMR studies indicate glycolytic dysfunctions in HD (Jenkins, Rosas et 
al. 1998), this seems particularly relevant. 
 
Microarray technology would be an excellent means of looking at the mRNA 
transcripts that are up- or down- regulated, in the presence of intracellular misfolded 
protein, and hopefully this would provide clues to identify and begin to elucidate new 
astrocytic functional deficits. There have been a number of recent microarray studies,  
performed on the whole brain of patients, or on models, with neurodegenerative 
disorders: e.g. (Blalock, Geddes et al. 2004; Cha 2007; Ferraiuolo, Heath et al. 2007) 
and there are a few papers published on the microarray analysis of astrocytes, in order 
to identify the gene expression profile unique to that cell type (Bachoo, Kim et al. 
2004; Daginakatte, Gadzinski et al. 2008; Hatada, Namihira et al. 2008; Obayashi, 
Tabunoki et al. 2009). However, no one has yet looked at how global mRNA 
expression levels change within astrocytes in the presence of abnormal protein or 
within a disease context. This is especially relevant, given the transcriptional 
dysregulation in HD (Benn, Sun et al. 2008).  Furthermore, it might be informative to 
compare the mRNA changes, seen in neurons, due to the presence of potentially 
damaging protein, to those in astrocytes. Unlike many other neurodegenerative 
diseases, the mutant protein in HD is present from conception and, hence, there might 
well be developmental defects that arise from that. Ideally one would derive neural 
stem cells from a control and an appropriate transgenic mouse model and differentiate 
these into neurons and astrocytes before performing the microarrays on all six 
populations. According to a Dr. Gray (Personal Communication, Southampton 
University, Neurology) and Dr. Stephen Minger (Personal Communication, King’s 
College, London), the average purity of a neuron culture derived from neural stem 
cells is around 30% so making a three way comparison might be difficult.  Although 
possibly one could use laser microdisection to isolate a patch of neurons from the 
above cultures to use for the microarrays. The production of astrocytes from stem  
cells, as a preface to microarray analysis, has precedence.  Both Bachoo, Kim et al. 
(2004) and Obayashi, Tabunoki et al. (2009) have done this. The earlier paper used 
this method to identify genes that were specific to astrocytes, or upregulated in 
astrocytes, in comparison to neural stem cells. They also showed that cortical 
astrocytes and astrocytes derived from stem cells were highly similar in their 
expression profiles. The more recent paper was performed in an attempt to understand 
the process by which astrocytes differentiate from their progenitors.  
 
In conclusion, astrocytes, the most common cell type in the brain, are amongst 
the, if not the, least studied cell types in neurodegeneration research.  However, 
dysfunction of these cells clearly contributes to pathology and studying them should 
prove rewarding.  The recent mouse models developed by the Li laboratory 
(Bradford, Shin et al. 2009; Bradford, Shin et al. 2010) where mutant htt is selectively 
expressed in astrocytes would be invaluable for any such investigation.  
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Appendix -Small Heat Shock Proteins 
 
    Several of the laboratories in the Boldrewood Neuroscience department, 
including the Wyttenbach lab have an interesting the role of small heat shock proteins 
(sHSPs) in neurodegeneration (See also the appended literature review).  In the 
interest of preserving the methods and data from my contribution to this work I 
include this appendix.   Heat shock proteins (HSPs) are molecular chaperones that 
temporarily bind to and stabilize other cellular proteins.  In disease, they aid the cell 
by preventing proteins from abnormal folding and aggregation (Saibil 2000).  sHSPs 
are a subclass of heat shock protein, implicated in neurodegenerative disease (Sun and 
MacRae 2005).  Out of a total of 10 sHSPs expressed in mammals, 5 of these are 
expressed in the CNS: HSP 20, HSP 22 HSP25, Hsp27 and αB-Crystallin, ABC 
(Quraishe, Asuni et al. 2008). Of these, HSP27, HSP25, HSP20 and ABC have been 
shown to be expressed in astrocytes (Acarin, Paris et al. 2002; Strey, Spellman et al. 
2004; Wilhelmus, Otte-Holler et al. 2006).  It is unknown whether HSP22 is also 
expressed in astrocytes. After an excitotoxic lesion, HSP27 was mainly expressed in 
astrocytes (Acarin, Paris et al. 2002).  HSP27 had previously been shown to increase 
glutathione levels and protect against oxidative stress in other cell types (Mehlen, 
Hickey et al. 1997). Astrocyte activation via IL1β also serves to increase their 
intracellular HSP27 levels (Saura, Pares et al. 2003).  HSP27 and ABC has also been 
shown to be induced in astrocytes in tauopathies, prion disease and AD (Dabir, 
Trojanowski et al. 2004).  In mouse models of ALS, HSP25 is upregulated in reactive 
astrocytes but lost in vulnerable motor neurons.  The latter is due to direct mutant 
SOD1 binding to and inhibition of HSP25 (Strey, Spellman et al. 2004).  Overall, the 
presence and importance of sHSPs, within astrocytes, during protein misfolding 
stress, merits attention. 
 
 
 
 
 
  
Methods 
Transformation and production of DNA 
For later use in the HSP side project, see index, we prepared stocks of HSP20, 
HSP22, HSP25, HSP27, Htt-Q25-GFP, Htt-Q103-GFP plasmids through the 
following method. DH5α cells were thawed on wet ice and gently mixed with a 
pipette tip. 1µl of plasmid (10-500ng concentration) was added to DH5α cells and 
then kept on ice for 30 minutes. Cells were heat shocked for 15 sec at 37 ºC in a water 
bath. Cells were incubated on ice for 2 minutes and then 0.9ml of pre-warmed 
sterilised LB media was added and incubated again at 37ºC in a water bath for 45 
minutes. 100µl of media-containing cells were streaked on a plate and incubated 
overnight at 37ºC.   
 
Plates were prepared, by heating 500mL of LB agar, in the microwave, and 
then cooling it to 40-50ºC. All plasmids except HSP20 had an ampicillin resistant 
gene. The HSP20 plasmid, sent to us by B. Rainer, Nationwide Children’s Hospital, 
OH, USA, is kanamycin resistant.  A 1:1000 dilution of ampicillin or kanamycin 
(SIGMA,UK, 100 mg/ml stock concentration) was added.  20 ml of LB agar media, 
containing the appropriate antibiotic, was poured for each plate, by using aseptic 
techniques. 25 µl of a maxi prep purified DNA was produced as follows: a single 
colony was picked from a resistant plate, grown overnight as above, and placed in a 
5mL tube of LB media containing 5µl of ampicillin or kanamycin (100mg/ml stock 
concentration). The culture was incubated for 6 hrs at 37ºC on a shaker.  After this, 
100µl of the starter culture was added to a flask, containing 100mls of sterilised LB 
media with the appropriate antibiotic, and then incubated overnight at 37ºC on a 
shaker. Bacterial cells were harvested by spinning at 6000 x g for 15 minutes at 4ºC. 
The pellet was re-suspended in 10 ml of buffer P1 containing RNase A (provided with 
QIAGEN EndoFree maxi plasmid purification kit). Subsequently, 10 ml of buffer P2 
was added and mixed thoroughly, by vigorously inverting the tube 5-6 times, and then 
incubated at room temperature for 5 minutes. 10 ml of ice cold buffer P3 was added to 
the lysate, and mixed instantly and thoroughly by inverting the tube 5-6 times. The 
lysate was poured into a barrel of the QIAfilter cartridge and incubated at room  
temperature for 10 minutes, then the plunger was gently inserted into the QIAfilter 
Maxi Cartridge and the lysate was filtered into a 50 ml tube.  
 2.5 ml of buffer ER was added to the filtered lysate, mixed by inverting the tube and 
incubated on ice for 30 minutes. The QIAGEN-tip 500 was equilibrated, by applying 
10ml of buffer QBT, and the column was allowed to empty by gravity flow. The 
filtered lysate was poured to the QIAGEN-tip and allowed to enter the resin by 
gravity flow. The QIAGEN-tip was washed with 2 x 30 ml buffer QC and the DNA 
was eluted with 15ml of buffer QN. Eluted DNA was precipitated by adding 10.5ml 
of isopropanol, mixed and centrifuged instantly at 5000 x g for 1 hour at 4 ºC. The 
supernatant was carefully removed and the DNA pellet was washed with 5ml of 
endotoxin-free 70 % ethanol and centrifuged again at 5000x g for 30 minutes. 
Carefully decanted, the supernatant and DNA pellet were dried for 5-10 minutes. The 
DNA pellet was resuspended with 200µl of molecular biology water.  DNA was then 
sent to Eurofins for sequencing. The analysis is provided in the index.  Also, to check 
the integrity of the DNA, the experiment described below was performed. 
Agarose gel electrophoresis 
1% agarose gels were made, by dissolving 0.6g of agarose in 60ml tris acetate 
(1xTAE) and heating in a microwave. The molten agarose was allowed to slightly 
cool down and ethidium bromide was added in a 1:2000 dilution.  Gels were poured 
into the electrophoresis chambers and gel combs were installed and gels were allowed 
to set. Electrophoresis tanks were filled with 1xTAE buffer and gel combs were taken 
off.  Wells in the gels were washed carefully by pipeting TAE buffer up and down.  
Samples were mixed with 6X loading dye to achieve 1X final concentration. Samples 
were loaded into the wells along with a molecular marker (1Kb DNA ladder, 
Invitrogen) in order to determine the size of DNA bands.  Gels were run at 65mV for 
20-40minutes.  
 
Plasmid Results. 
 
I have made some headway with the project described in 6.1.  I have expanded via 
Maxiprep, measured the concentration and integrity of  Htt25,72,97-Exon1-GFP (Fig 
20), HSP27, HSP22 and ABC plasmids (Fig 22)  and sequenced Htt25,72,97-Exon1- 
GFP (Fig-21), HSP27 and ABC (Fig 23 A ,B).   I have also produced some stocks of 
astrocyte, HeLa cell and SH-5Y5Y lysates which shall be used to establish the 
endogenous resting sHSP protein levels in these cell types.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       1      2      3     4      5     6 
 
Fig 20. 200ng (1,4,7, 100ng (2,5,8) and 50ng (3,6,9) of plasmid.  Htt 25 plasmid 
(1-3, Htt72 plasmid (4-6) and Htt97 plasmid (7-9).  Gel confirms that our 
nanodrop concentration measurements are accurate.   
   1         2        3        4      5        6      7         8        9 
GENE ID: 3064 HTT | huntingtin [Homo sapiens] 
Score =  261 bits (141),  Expect = 9e-67 
 Identities = 236/282 (83%), Gaps = 6/282 (2%) 
 
Query  125  GACCGCCATGGCGACCCTGGAAAAGCTGATGAAGGCCTTCGAGTCCCTCAAAAGCTTCCA  184 
Sbjct  139    GACCGCCATGGCGACCCTGGAAAAGCTGATGAAGGCCTTCGAGTCCCTCAAGTCCTTCCA  198 
 
Query  185  ACAGCAGCAACAGCAACAACAGCAGCAACAGCAACAACAGCAGCAACAGCAACAACAGCA  244 
Sbjct    199  GCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCA  258 
 
Query  245  GCAACAGCAACAACCGCCACCACCTCCCCCTCCACCCCCACCTCCTCAACTTCCTCAACC  304 
  Sbjct  259 GCAACAGC--------------GCCACCGCCGCCGCCGCCGCCGCCGCCTCCTCAGCTTCCTCAGCC  312 
 
Query  305  TCCTCCACAGGCACAGCCTCTGCTGCCTCAGCCACAACCTCCTCCACCTCCACCTCCACC  364 
Sbjct  313  GCCGCCGCAGGCACAGCCGCTGCTGCCTCAGCCGCAGCCGCCCCCGCCGCCGCCCCCGCC  372 
 
Query  365  TCCTCCAGGCCCAGCTGTGGCTGAGGAGCCTCTGCACCGACC  406 
  Sbjct  373  GCCACCCGGCCCGGCTGTGGCTGAGGAGCCGCTGCACCGACC  414 
Fig 21.  Our Htt Q97 swquence aligned with the pubmed nucleotide database 
 
   1         2        3        4        5        6        7        8        9 
Fig 22. 200ng (1,4,7, 100ng (2,5,8) and 50ng (3,6,9) of plasmid.  HSP22 (1-3), 
HSP27 (4-6) and ABC (7-9).  Gel confirms that our nanodrop concentration 
measurements are accurate.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GENE ID: 1410 CRYAB | crystallin, alpha B [Homo sapiens] 
Score =  894 bits (484),  Expect = 0.0 
 Identities = 488/490 (99%), Gaps = 0/490 (0%) 
 
Query  107  CATGGACATCGCCATCCACCACCCCTGGATCCGCCGCCCCTTCTTTCCTTTCCACTCCCC  166 
  Sbjct  25   CATGGACATCGCCATCCACCACCCCTGGATCCGCCGCCCCTTCTTTCCTTTCCACTCCCC  84 
 
Query  167  CAGCCGCCTCTTCGACCAGTTCTTCGGAGAGCACCTGTTGGAGTCTGATCTTTTCCCGAC  226 
   Sbjct  85   CAGCCGCCTCTTTGACCAGTTCTTCGGAGAGCACCTGTTGGAGTCTGATCTTTTCCCGAC  144 
 
Query  227  GTCTACTTCCCTGAGTCCCTTCTACCTTCGGCCACCCTCCTTCCTGCGGGCACCCAGCTG  286 
  Sbjct  145  GTCTACTTCCCTGAGTCCCTTCTACCTTCGGCCACCCTCCTTCCTGCGGGCACCCAGCTG  204 
 
Query  287  GTTTGACACTGGACTCTCAGAGATGCGCCTGGAGAAGGACAGGTTCTCTGTCAACCTGGA  346 
  Sbjct  205  GTTTGACACTGGACTCTCAGAGATGCGCCTGGAGAAGGACAGGTTCTCTGTCAACCTGGA  264 
 
Query  347  TGTGAAGCACTTCTCCCCAGAGGAACTCAAAGTTAAGGTGTTGGGAGATGTGATTGAGGT  406 
  Sbjct  265  TGTGAAGCACTTCTCCCCAGAGGAACTCAAAGTTAAGGTGTTGGGAGATGTGATTGAGGT  324 
 
Query  407  GCATGGAAAACATGAAGAGCGCCAGGATGAACATGGTTTCATCTCCAGGGAGTTCCACAG  466 
  Sbjct  325  GCATGGAAAACATGAAGAGCGCCAGGATGAACATGGTTTCATCTCCAGGGAGTTCCACAG  384 
 
Query  467  GAAATACCGGATCCCAGCTGATGTAGACCCTCTCACCATTACTTCATCCCTGTCATCTGA  526 
 Sbjct  385  GAAATACCGGATCCCAGCTGATGTAGACCCTCTCACCATTACTTCATCCCTGTCATCTGA  444 
 
Query  527  TGGGGTCCTCACTGTGAATGGACCAAGGAAACAGGTCTCTGGCCCTGAGCGCACCATTCC  586 
 Sbjct  445  TGGGGTCCTCACTGTGAATGGACCAAGGAAACAGGTCTCTGGCCCTGAGCGCACCATTCC  504 
 
Query  587  CATCACACGT  596 
  Sbjct  505  CATCACCCGT  514 
Fig 23. A.  Our αβC plasmid sequence aligned with the pubmed nucleotide 
database.  
Astrocytes and Small Heat Shock Proteins 
 
  Previous work by Dr. Darrington in the Wyttenbach lab showed that HSP22 & 
ABC colocalize with hhtEx1-Q103-EGFP inclusion bodies in Hela cells and 
astrocytes, overexpression of HSP 27, HSP22 and ABC reduces cell death in HeLa 
and SH-SY5Y cells and HSP22 and ABC reduce inclusion body formation in Hela 
cells.  Dr. Darrington also showed high levels of endogenous ABC expression. 
 
Astrocytes express ABC, HSP27, HSP25 and HSP20. I showed that ABC 
and  HSP27, in rare instances (<1%), co-localize with intracellular Htt aggregates 
(5c,d).  Possibly the formation of larger aggregates of htt protein is protective and 
sHSPs have been shown to aid in the formation of these aggregates, also htt 
aggregates have been shown to sequester various intracellular proteins and, 
potentially, this includes sHSPs ((Sakahira, Breuer et al. 2002; Liberek, 
Lewandowska et al. 2008).   
 
 
 
Homo sapiens heat shock 27kDa protein 1 (HSPB1), mRNA 
Length=865 
 
 
 Score =  743 bits (402),  Expect = 0.0 
 Identities = 404/405 (99%), Gaps = 0/405 (0%) 
 Strand=Plus/Plus 
 
Query  87  GCATGACCGAGCGCCGCGTCCCCTTCTCGCTCCTGCGGGGCCCCAGCTGGGACCCCTTCC  146             
 Sbjct 106  GCATGACCGAGCGCCGCGTCCCCTTCTCGCTCCTGCGGGGCCCCAGCTGGGACCCCTTCC  165 
 
Query  147  GCGACTGGTACCCGCATAGCCGCCTCTTCGACCAGGCCTTCGGGCTGCCCCGGCTGCCGG  206 
Sbjct    166  GCGACTGGTACCCGCATAGCCGCCTCTTCGACCAGGCCTTCGGGCTGCCCCGGCTGCCGG  225 
 
Query  207  AGGAGTGGTCGCAGTGGTTAGGCGGCAGCAGCTGGCCAGGCTACGTGCGCCCCCTGCCCC  266 
Sbjct  226    AGGAGTGGTCGCAGTGGTTAGGCGGCAGCAGCTGGCCAGGCTACGTGCGCCCCCTGCCCC  285 
 
Query  267  CCGCCGCCATCGAGAGCCCCGCAGTGGCCGCGCCCGCCTACAGCCGCGCGCTCAGCCGGC  326 
Sbjct  286    CCGCCGCCATCGAGAGCCCCGCAGTGGCCGCGCCCGCCTACAGCCGCGCGCTCAGCCGGC  345 
 
Query  327  AACTCAGCAGCGGGGTCTCGGAGATCCGGCACACTGCGGACCGCTGGCGCGTGTCCCTGG  386 
Sbjct  346    AACTCAGCAGCGGGGTCTCGGAGATCCGGCACACTGCGGACCGCTGGCGCGTGTCCCTGG  405 
 
Query  387  ATGTCAACCACTTCGCCCCGGACGAGCTGACGGTCAAGACCAAGGATGGCGTGGTGGAGA  446 
Sbjct  406    ATGTCAACCACTTCGCCCCGGACGAGCTGACGGTCAAGACCAAGGATGGCGTGGTGGAGA  465 
 
Query  447  TCACCGGCAAGCACGAGGAGCGGCAGGACGAGCATGGCCACATCT  491 
Sbjct  466    TCACCGGCAAGCACGAGGAGCGGCAGGACGAGCATGGCTACATCT  510 
 
 
Fig 23. B.  Our HSP27 plasmid se quence aligned with the pubmed nucleotide 
database.  
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Fig 24. A.) Astrocytes grown on laminin. Goat anti Rabbit 555 secondary antibody 
only. 40x B.) Astrocytes grown on laminin.  Anti-ABC staining.  No Q97 adenovirus. 
40x C.) Astrocytes grown on laminin. Anti-HSP-27 staining. 40x D.) Astrocytes 
grown on laminin. Goat anti-Rabbit 555 secondary antibody only. 40x 
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Fig  24. E.) Astrocytes grown on laminin, infected with Q97-GFP adenovirus, stained 
with anti-ABC antibody.  I. Blue channel, DAPI-stained nuclei.  II. Q97-GFP indicating 
presence of Htt (detector gain 600).   III.  Q97-GFP (detector gain 350) potentially 
indicating more solid aggregate.  IV. Anti-ABC staining.   V. Overlay of channels.  Note 
that the strongest ABC staining from IV surrounds the body seen in III, providing strong 
evidence that this co-localization event is genuine. 63x 
F.) Astrocytes grown on laminin, infected with Q97-GFP adenovirus, stained with anti-
ABC antibody..  I. Blue channel, DAPI-stained nuclei.  II. Q97-GFP indicating presence 
of Htt (detector gain 600).   III.  Q97-GFP (detector gain 350) potentially indicating more 
solid aggregate.  IV. Anti-ABC staining.   V. Overlay of channels.  Note that the strongest 
ABC staining from IV surrounds the body seen in III, providing strong evidence that this 
co-localization event is genuine. 63x 
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